Go to MainR2: R2 Citations in PubMed
Help (RtD)

Publications that made use of/cited the R2 platform

2018 (n=150)
773Kerosuo L et.al. (2018). Enhanced expression of MycN/CIP2A drives neural crest toward a neural stem cell-like fate: Implications for priming of neuroblastoma. Proc Natl Acad Sci U S A :.
772Cavalli FMG et.al. (2018). Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathol :.
771Li T et.al. (2018). Brutons tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma. Oncogene :.
770Bielli P et.al. (2018). The splicing factor PTBP1 promotes expression of oncogenic splice variants and predicts poor prognosis in patients with non-muscle invasive bladder cancer. Clin Cancer Res :.
769Breunig C et.al. (2018). TGFbeta1 regulates HGF-induced cell migration and hepatocyte growth factor receptor MET expression via C-ets-1 and miR-128-3p in basal-like breast cancer. Mol Oncol :.
768Akgul S et.al. (2018). Opposing Tumor-Promoting and -Suppressive Functions of Rictor/mTORC2 Signaling in Adult Glioma and Pediatric SHH Medulloblastoma. Cell Rep 24:463-478.e5.
767Idichi T et.al. (2018). Involvement of anti-tumor miR-124-3p and its targets in the pathogenesis of pancreatic ductal adenocarcinoma: direct regulation of ITGA3 and ITGB1 by miR-124-3p. Oncotarget 9:28849-28865.
766Lehrer S et.al. (2018). Loss of MycBP may be associated with the improved survival in 1P co-deletion of lower grade glioma patients. Clin Neurol Neurosurg 172:112-115.
765Subbarayan K et.al. (2018). Tumor-dependent effects of proteoglycans and various glycosaminoglycan synthesizing enzymes and sulfotransferases on patients outcome. Curr Cancer Drug Targets :.
764Liang KH et.al. (2018). Extracellular domain of EpCAM enhances tumor progression through EGFR signaling in colon cancer cells. Cancer Lett :.
763Uhl KL et.al. (2018). Harmine, a dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor induces caspase-mediated apoptosis in neuroblastoma. Cancer Cell Int 18:82.
762Lehrer S et.al. (2018). Glioblastoma Multiforme: Fewer Tumor Copy Number Segments of the SGK1 Gene Are Associated with Poorer Survival. Cancer Genomics Proteomics 15:273-278.
761Tao Y et.al. (2018). Alternative NF-kappaB signaling promotes colorectal tumorigenesis through transcriptionally upregulating Bcl-3. Oncogene :.
760Santhana Kumar K et.al. (2018). TGF-beta Determines the Pro-migratory Potential of bFGF Signaling in Medulloblastoma. Cell Rep 23:3798-3812.e8.
759Pieraccioli M et.al. (2018). ZNF281 inhibits neuronal differentiation and is a prognostic marker for neuroblastoma. Proc Natl Acad Sci U S A :.
758Mansour MR et.al. (2018). JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia. J Exp Med :.
757Bettinsoli P et.al. (2018). Favorable prognostic role of tropomodulins in neuroblastoma. Oncotarget 9:27092-27103.
756Liang L et.al. (2018). CD271+ cells are diagnostic and prognostic and exhibit elevated MAPK activity in SHH medulloblastoma. Cancer Res :.
755Duan K et.al. (2018). Lactic acid induces lactate transport and glycolysis/OXPHOS interconversion in glioblastoma. Biochem Biophys Res Commun :.
754Ou-Yang Q et.al. (2018). TRPV4 promotes the migration and invasion of glioma cells via AKT/Rac1 signaling. Biochem Biophys Res Commun :.
753Yamada Y et.al. (2018). Anti-tumor roles of both strands of the miR-455 duplex: their targets SKA1 and SKA3 are involved in the pathogenesis of renal cell carcinoma. Oncotarget 9:26638-26658.
752Lee NH et.al. (2018). SERPINB2 is a novel indicator of stem cell toxicity. Cell Death Dis 9:724.
751Bruggeman JW et.al. (2018). Massive expression of germ cell-specific genes is a hallmark of cancer and a potential target for novel treatment development. Oncogene :.
750Hua T et.al. (2018). Estrogenrelated receptor gamma promotes the migration and metastasis of endometrial cancer cells by targeting S100A4. Oncol Rep :.
749Ognibene M et.al. (2018). CHL1 gene acts as a tumor suppressor in human neuroblastoma. Oncotarget 9:25903-25921.
748Chen C et.al. (2018). Downregulation of histone demethylase JMJD1C inhibits colorectal cancer metastasis through targeting ATF2. Am J Cancer Res 8:852-865.
747Mari L et.al. (2018). microRNA 125a Regulates MHC-I Expression on Esophageal Adenocarcinoma Cells, Associated With Suppression of Anti-tumor Immune Response and Poor Outcomes of Patients. Gastroenterology :.
746Li Y et.al. (2018). miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma. J Neurooncol :.
745Bader S et.al. (2018). Effect of the actin and calcium-regulating activities of ITPKB on the metastatic potential of lung cancer cells. Biochem J 475:2057-2071.
744Han T et.al. (2018). Forkhead box D1 promotes proliferation and suppresses apoptosis via regulating polo-like kinase 2 in colorectal cancer. Biomed Pharmacother 103:1369-1375.
743Zheng L et.al. (2018). STARD13-correlated ceRNA network-directed inhibition on YAP/TAZ activity suppresses stemness of breast cancer via co-regulating Hippo and Rho-GTPase/F-actin signaling. J Hematol Oncol 11:72.
742Gu C et.al. (2018). FSTL1 interacts with VIM and promotes colorectal cancer metastasis via activating the focal adhesion signalling pathway. Cell Death Dis 9:654.
741Tripolitsioti D et.al. (2018). MAP4K4 controlled integrin beta1 activation and c-Met endocytosis are associated with invasive behavior of medulloblastoma cells. Oncotarget 9:23220-23236.
740De Santo C et.al. (2018). Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma. J Hematol Oncol 11:68.
739Lochmann TL et.al. (2018). Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma. Sci Transl Med 10:.
738Yi L et.al. (2018). Bioinformatic analyses reveal the key pathways and genes in the CXCR4 mediated mesenchymal subtype of glioblastoma. Mol Med Rep :.
737Taye N et.al. (2018). SMAR1 inhibits Wnt/beta-catenin signaling and prevents colorectal cancer progression. Oncotarget 9:21322-21336.
736Miyazaki M et.al. (2018). The p53 activator overcomes resistance to ALK inhibitors by regulating p53-target selectivity in ALK-driven neuroblastomas. Cell Death Discov 4:56.
735Liu C et.al. (2018). PRDM1 silences stem cell-related genes and inhibits proliferation of human colon tumor organoids. Proc Natl Acad Sci U S A 115:E5066-E5075.
734Agarwal S et.al. (2018). MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma. Oncotarget 9:20323-20338.
733Lehrer S et.al. (2018). In primary glioblastoma fewer tumor copy number segments of the F13A1 gene are associated with poorer survival. Thromb Res 167:12-14.
732Menard M et.al. (2018). Hey1 PLoS Biol 16:e2002912.
731Ishizuka Y et.al. (2018). NRP1 knockdown promotes the migration and invasion of human neuroblastoma-derived SKNAS cells via the activation of beta1 integrin expression. Int J Oncol 53:159-166.
730Tong L et.al. (2018). Tumour cell dormancy as a contributor to the reduced survival of GBM patients who received standard therapy. Oncol Rep 40:463-471.
729Parry AJ et.al. (2018). NOTCH-mediated non-cell autonomous regulation of chromatin structure during senescence. Nat Commun 9:1840.
728Chai P et.al. (2018). Dynamic chromosomal tuning of a novel GAU1 lncing driver at chr12p13.32 accelerates tumorigenesis. Nucleic Acids Res :.
727Zhang T et.al. (2018). Angiopoietin-like 4 promotes osteosarcoma cell proliferation and migration and stimulates osteoclastogenesis. BMC Cancer 18:536.
726Wang Y et.al. (2018). Neutrophils infiltrating pancreatic ductal adenocarcinoma indicate higher malignancy and worse prognosis. Biochem Biophys Res Commun 501:313-319.
725Liu Q et.al. (2018). SPOCD1 promotes the proliferation and metastasis of glioma cells by up-regulating PTX3. Am J Cancer Res 8:624-635.
724Zheng L et.al. (2018). RNA Binding Protein RNPC1 Inhibits Breast Cancer Cell Metastasis via Activating STARD13-Correlated ceRNA Network. Mol Pharm 15:2123-2132.
723Trumpi K et.al. (2018). Macrophages induce budding in aggressive human colon cancer subtypes by protease-mediated disruption of tight junctions. Oncotarget 9:19490-19507.
722Padua MB et.al. (2018). Dependence receptor UNC5A restricts luminal to basal breast cancer plasticity and metastasis. Breast Cancer Res 20:35.
721Engel N et.al. (2018). First evidence of SGPL1 expression in the cell membrane silencing the extracellular S1P siren in mammary epithelial cells. PLoS One 13:e0196854.
720Madhav A et.al. (2018). Antagonizing CD105 enhances radiation sensitivity in prostate cancer. Oncogene :.
719Sanghez V et.al. (2018). Efficacy of Asparaginase Erwinia chrysanthemi With and Without Temozolomide Against Glioma Cells and Intracranial Mouse Medulloblastoma. Anticancer Res 38:2627-2634.
718Berenguer J et.al. (2018). Glycosylated extracellular vesicles released by glioblastoma cells are decorated by CCL18 allowing for cellular uptake via chemokine receptor CCR8. J Extracell Vesicles 7:1446660.
717Chen J et.al. (2018). Promotion of Tumor Growth by ADAMTS4 in Colorectal Cancer: Focused on Macrophages. Cell Physiol Biochem 46:1693-1703.
716E Hermosilla V et.al. (2018). SALL2 represses cyclins D1 and E1 expression and restrains G1/S cell cycle transition and cancer-related phenotypes. Mol Oncol :.
715Sime W et.al. (2018). BAP1 induces cell death via interaction with 14-3-3 in neuroblastoma. Cell Death Dis 9:458.
714Kuipers AJ et.al. (2018). TRPM7 controls mesenchymal features of breast cancer cells by tensional regulation of SOX4. Biochim Biophys Acta 1864:2409-2419.
713Xu Q et.al. (2018). MicroRNA-876-5p inhibits epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma by targeting BCL6 corepressor like 1. Biomed Pharmacother 103:645-652.
712Muller S et.al. (2018). IGF2BP1 enhances an aggressive tumor cell phenotype by impairing miRNA-directed downregulation of oncogenic factors. Nucleic Acids Res :.
711Chen D et.al. (2018). Super enhancer inhibitors suppress MYC driven transcriptional amplification and tumor progression in osteosarcoma. Bone Res 6:11.
710Park JW et.al. (2018). Sprouty2 enhances the tumorigenic potential of glioblastoma cells. Neuro Oncol :.
709Subbarayan K et.al. (2018). Biglycan-mediated upregulation of MHC class I expression in HER-2/neu-transformed cells. Oncoimmunology 7:e1373233.
708Joly AL et.al. (2018). Alternative Splicing of FOXP3 Controls Regulatory T Cell Effector Functions and Is Associated With Human Atherosclerotic Plaque Stability. Circ Res 122:1385-1394.
707Stephenson L et.al. (2018). Building online genomics applications using BioPyramid. Bioinformatics :.
706Wu Y et.al. (2018). Suv4-20h1 promotes G1 to S phase transition by downregulating p21(WAF1/CIP1) expression in chronic myeloid leukemia K562 cells. Oncol Lett 15:6123-6130.
705Mettang M et.al. (2018). Blocking distinct interactions between Glioblastoma cells and their tissue microenvironment: A novel multi-targeted therapeutic approach. Sci Rep 8:5527.
704Orlando D et.al. (2018). Adoptive immunotherapy using PRAME-specific T cells in medulloblastoma. Cancer Res :.
703Khanna S et.al. (2018). Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients. Clin Cancer Res :.
702Valvona CJ et.al. (2018). Oxamate, but Not Selective Targeting of LDH-A, Inhibits Medulloblastoma Cell Glycolysis, Growth and Motility. Brain Sci 8:.
701Xu W et.al. (2018). Knockdown of HuR represses osteosarcoma cells migration, invasion and stemness through inhibition of YAP activation and increases susceptibility to chemotherapeutic agents. Biomed Pharmacother 102:587-593.
700Hamidian A et.al. (2018). Promoter-associated proteins of EPAS1 identified by enChIP-MS Biochem Biophys Res Commun 499:291-298.
699Nikitovic D et.al. (2018). Proteoglycans-Biomarkers and Targets in Cancer Therapy. Front Endocrinol (Lausanne) 9:69.
698Kawano Y et.al. (2018). Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression. J Clin Invest 128:2487-2499.
697Neidert MC et.al. (2018). The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy. Acta Neuropathol 135:923-938.
696He J et.al. (2018). Cancer-testis Specific Gene OIP5: A Downstream Gene of E2F1 that Promotes Tumorigenesis and Metastasis in Glioblastoma by Stabilizing E2F1 Signalling. Neuro Oncol :.
695Hossain MM et.al. (2018). Hyperactivation of nuclear receptor coactivators induces PERK-dependent cell death. Oncotarget 9:11707-11721.
694Revert F et.al. (2018). Selective targeting of collagen IV in the cancer cell microenvironment reduces tumor burden. Oncotarget 9:11020-11045.
693Li C et.al. (2018). Long non-coding RNA KCNQ1OT1 mediates the growth of hepatocellular carcinoma by functioning as a competing endogenous RNA of miR-504. Int J Oncol :.
692Tan IL et.al. (2018). Lateral cerebellum is preferentially sensitive to high sonic hedgehog signaling and medulloblastoma formation. Proc Natl Acad Sci U S A 115:3392-3397.
691Wang H et.al. (2018). HER4 promotes cell survival and chemoresistance in osteosarcoma via interaction with NDRG1. Biochim Biophys Acta 1864:1839-1849.
690Zhao SJ et.al. (2018). SLIT2/ROBO1 axis contributes to the Warburg effect in osteosarcoma through activation of SRC/ERK/c-MYC/PFKFB2 pathway. Cell Death Dis 9:390.
689Ma Y et.al. (2018). The tumor suppressive miR-26a regulation of FBXO11 inhibits proliferation, migration and invasion of hepatocellular carcinoma cells. Biomed Pharmacother 101:648-655.
688Shen J et.al. (2018). A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment. Cell Death Differ :.
687Depuydt P et.al. (2018). Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. J Natl Cancer Inst :.
686Paquet-Fifield S et.al. (2018). Tight Junction Protein Claudin-2 Promotes Self-Renewal of Human Colorectal Cancer Stem-like Cells. Cancer Res 78:2925-2938.
685Garcia-Heredia JM et.al. (2018). NUMB and NUMBL differences in gene regulation. Oncotarget 9:9219-9234.
684Boulagnon-Rombi C et.al. (2018). LRP1 expression in colon cancer predicts clinical outcome. Oncotarget 9:8849-8869.
683Li Z et.al. (2018). EZH2 regulates neuroblastoma cell differentiation via NTRK1 promoter epigenetic modifications. Oncogene 37:2714-2727.
682Szemes M et.al. (2018). Wnt Signalling Drives Context-Dependent Differentiation or Proliferation in Neuroblastoma. Neoplasia 20:335-350.
681Fregni G et.al. (2018). Reciprocal modulation of mesenchymal stem cells and tumor cells promotes lung cancer metastasis. EBioMedicine 29:128-145.
680Michaelsen SR et.al. (2018). DNA Methylation Levels of the ELMO Gene Promoter CpG Islands in Human Glioblastomas. Int J Mol Sci 19:.
679Ferrucci V et.al. (2018). Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-TGF-beta-OTX2-SNAIL via PTEN inhibition. Brain 141:1300-1319.
678Grobner SN et.al. (2018). The landscape of genomic alterations across childhood cancers. Nature 555:321-327.
677Floros KV et.al. (2018). Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy. Proc Natl Acad Sci U S A 115:E2594-E2603.
676OBrien EM et.al. (2018). The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells. BMC Cancer 18:217.
675Jin F et.al. (2018). High-density lipoprotein (HDL) promotes angiogenesis via S1P3-dependent VEGFR2 activation. Angiogenesis 21:381-394.
674Sun H et.al. (2018). CFTR mutation enhances Dishevelled degradation and results in impairment of Wnt-dependent hematopoiesis. Cell Death Dis 9:275.
673Brunen D et.al. (2018). PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma. Mol Cancer Ther 17:849-857.
672Li W et.al. (2018). Sirtuin7 has an oncogenic potential via promoting the growth of cholangiocarcinoma cells. Biomed Pharmacother 100:257-266.
671Karachaliou N et.al. (2018). Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis. EBioMedicine 29:112-127.
670Yu Y et.al. (2018). Tumor suppressive ZBTB4 inhibits cell growth by regulating cell cycle progression and apoptosis in Ewing sarcoma. Biomed Pharmacother 100:108-115.
669Guan S et.al. (2018). MELK is a novel therapeutic target in high-risk neuroblastoma. Oncotarget 9:2591-2602.
668Arnhold V et.al. (2018). Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma. Oncotarget 9:2304-2319.
667Tian T et.al. (2018). SNHG1 promotes cell proliferation by acting as a sponge of miR-145 in colorectal cancer. Oncotarget 9:2128-2139.
666Yanru W et.al. (2018). Transcriptomic analyses of chemokines reveal that down-regulation of XCR1 is associated with advanced hepatocellular carcinoma. Biochem Biophys Res Commun 496:1314-1321.
665Ferrucci F et.al. (2018). MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma. Biochim Biophys Acta 1861:235-245.
664Zhang H et.al. (2018). Expression profile and clinical significance of Wnt signaling in human gliomas. Oncol Lett 15:610-617.
663Gross A et.al. (2018). Tumorigenic and Antiproliferative Properties of the TALE-Transcription Factors MEIS2D and MEIS2A in Neuroblastoma. Cancer Res 78:1935-1947.
662Xiang S et.al. (2018). LncRNA IDH1-AS1 links the functions of c-Myc and HIF1alpha via IDH1 to regulate the Warburg effect. Proc Natl Acad Sci U S A 115:E1465-E1474.
661Dzieran J et.al. (2018). MYCN-amplified neuroblastoma maintains an aggressive and undifferentiated phenotype by deregulation of estrogen and NGF signaling. Proc Natl Acad Sci U S A 115:E1229-E1238.
660Folgiero V et.al. (2018). Che-1 is targeted by c-Myc to sustain proliferation in pre-B-cell acute lymphoblastic leukemia. EMBO Rep 19:.
659Yuan R et.al. (2018). Chk1 and 14-3-3 proteins inhibit atypical E2Fs to prevent a permanent cell cycle arrest. EMBO J 37:.
658Wu Q et.al. (2018). miR-375 inhibits IFN-gamma-induced programmed death 1 ligand 1 surface expression in head and neck squamous cell carcinoma cells by blocking JAK2/STAT1 signaling. Oncol Rep 39:1461-1468.
657Li X et.al. (2018). Retinoic acid promotes stem cell differentiation and embryonic development by transcriptionally activating CFTR. Biochim Biophys Acta 1865:605-615.
656Hasna J et.al. (2018). Orai3 calcium channel and resistance to chemotherapy in breast cancer cells: the p53 connection. Cell Death Differ 25:691-705.
655Chen S et.al. (2018). EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis. J Exp Clin Cancer Res 37:3.
654Zhang Y et.al. (2018). YAP Promotes Migration and Invasion of Human Glioma Cells. J Mol Neurosci 64:262-272.
653Schultz CR et.al. (2018). Synergistic drug combination GC7/DFMO suppresses hypusine/spermidine-dependent eIF5A activation and induces apoptotic cell death in neuroblastoma. Biochem J 475:531-545.
652Sun C et.al. (2018). F-box protein 11 promotes the growth and metastasis of gastric cancer via PI3K/AKT pathway-mediated EMT. Biomed Pharmacother 98:416-423.
651Han B et.al. (2018). FOXC1-induced non-canonical WNT5A-MMP7 signaling regulates invasiveness in triple-negative breast cancer. Oncogene 37:1399-1408.
650Khodaparast S et.al. (2018). Dewetting of Thin Liquid Films Surrounding Air Bubbles in Microchannels. Langmuir 34:1363-1370.
649Zhang T et.al. (2018). The atypical protein kinase RIOK3 contributes to glioma cell proliferation/survival, migration/invasion and the AKT/mTOR signaling pathway. Cancer Lett 415:151-163.
648Agrawal R et.al. (2018). p53 and miR-210 regulated NeuroD2, a neuronal basic helix-loop-helix transcription factor, is downregulated in glioblastoma patients and functions as a tumor suppressor under hypoxic microenvironment. Int J Cancer 142:1817-1828.
647Koster R et.al. (2018). Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients. Int J Cancer 142:1594-1601.
646Zhang B et.al. (2018). Neuroglobin promotes the proliferation and suppresses the apoptosis of glioma cells by activating the PI3K/AKT pathway. Mol Med Rep 17:2757-2763.
645Flannery PC et.al. (2018). Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma. Oncol Rep 39:455-464.
644Wang Z et.al. (2018). RNA binding protein Lin28A promotes osteocarcinoma cells progression by associating with the long noncoding RNA MALAT1. Biotechnol Lett 40:493-500.
643Lucena-Cacace A et.al. (2018). NAMPT Is a Potent Oncogene in Colon Cancer Progression that Modulates Cancer Stem Cell Properties and Resistance to Therapy through Sirt1 and PARP. Clin Cancer Res 24:1202-1215.
642Liu SM et.al. (2018). miR-596 Modulates Melanoma Growth by Regulating Cell Survival and Death. J Invest Dermatol 138:911-921.
641Hwang I et.al. (2018). FOXO protects against age-progressive axonal degeneration. Aging Cell 17:.
640Meel MH et.al. (2018). Signaling pathways and mesenchymal transition in pediatric high-grade glioma. Cell Mol Life Sci 75:871-887.
639Bogeas A et.al. (2018). Changes in chromatin state reveal ARNT2 at a node of a tumorigenic transcription factor signature driving glioblastoma cell aggressiveness. Acta Neuropathol 135:267-283.
638Panchoo M et.al. (2018). Scavenger receptor class B type 1 regulates neuroblastoma cell proliferation, migration and invasion. Biochem Biophys Res Commun 495:614-620.
637Lochmann TL et.al. (2018). Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression. Clin Cancer Res 24:360-369.
636Huang Y et.al. (2018). Three-dimensional hydrogel is suitable for targeted investigation of amoeboid migration of glioma cells. Mol Med Rep 17:250-256.
635Zhao SJ et.al. (2018). SPARCL1 suppresses osteosarcoma metastasis and recruits macrophages by activation of canonical WNT/beta-catenin signaling through stabilization of the WNT-receptor complex. Oncogene 37:1049-1061.
634Deng S et.al. (2018). Overexpression of COX7A2 is associated with a good prognosis in patients with glioma. J Neurooncol 136:41-50.
633Song KA et.al. (2018). Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM. Clin Cancer Res 24:197-208.
632Marturano-Kruik A et.al. (2018). Biomechanical regulation of drug sensitivity in an engineered model of human tumor. Biomaterials 150:150-161.
631Pahlman S et.al. (2018). Hypoxia and hypoxia-inducible factors in neuroblastoma. Cell Tissue Res 372:269-275.
630Ge Z et.al. (2018). Plant homeodomain finger protein 2 as a novel IKAROS target in acute lymphoblastic leukemia. Epigenomics 10:59-69.
629Wang CH et.al. (2018). Resistin facilitates breast cancer progression via TLR4-mediated induction of mesenchymal phenotypes and stemness properties. Oncogene 37:589-600.
628Narayan RS et.al. (2018). Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma. Mol Cancer Ther 17:347-354.
627Xie Z et.al. (2018). miR-149 promotes human osteocarcinoma progression via targeting bone morphogenetic protein 9 (BMP9). Biotechnol Lett 40:47-55.
626Rifatbegovic F et.al. (2018). Neuroblastoma cells undergo transcriptomic alterations upon dissemination into the bone marrow and subsequent tumor progression. Int J Cancer 142:297-307.
625Hasenoehrl C et.al. (2018). G protein-coupled receptor GPR55 promotes colorectal cancer and has opposing effects to cannabinoid receptor 1. Int J Cancer 142:121-132.
624Choo S et.al. (2018). Reactivation of TWIST1 contributes to Ewing sarcoma metastasis. Pediatr Blood Cancer 65:.
2017 (n=171)
623Leong WZ et.al. (2017). ARID5B as a critical downstream target of the TAL1 complex that activates the oncogenic transcriptional program and promotes T-cell leukemogenesis. Genes Dev 31:2343-2360.
622Lange I et.al. (2017). FTY-720 induces apoptosis in neuroblastoma via multiple signaling pathways. Oncotarget 8:109985-109999.
621Mu L et.al. (2017). Small-sized colorectal cancer cells harbor metastatic tumor-initiating cells. Oncotarget 8:107907-107919.
620Su Z et.al. (2017). Neurocan, an extracellular chondroitin sulfate proteoglycan, stimulates neuroblastoma cells to promote malignant phenotypes. Oncotarget 8:106296-106310.
619Verdugo-Sivianes EM et.al. (2017). Coordinated downregulation of Spinophilin and the catalytic subunits of PP1, PPP1CA/B/C, contributes to a worse prognosis in lung cancer. Oncotarget 8:105196-105210.
618Arrizabalaga O et.al. (2017). High expression of MKP1/DUSP1 counteracts glioma stem cell activity and mediates HDAC inhibitor response. Oncogenesis 6:401.
617Gong L et.al. (2017). Differential radiation response between normal astrocytes and glioma cells revealed by comparative transcriptome analysis. Onco Targets Ther 10:5755-5764.
616Mucignat-Caretta C et.al. (2017). Protein Kinase A Distribution Differentiates Human Glioblastoma from Brain Tissue. Cancers (Basel) 10:.
615Chen Z et.al. (2017). Small molecule inhibitor regorafenib inhibits RET signaling in neuroblastoma cells and effectively suppresses tumor growth in vivo. Oncotarget 8:104090-104103.
614Astrologo L et.al. (2017). ALK1Fc Suppresses the Human Prostate Cancer Growth in in Vitro and in Vivo Preclinical Models. Front Cell Dev Biol 5:104.
613Lucena-Cacace A et.al. (2017). NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis. Oncotarget 8:99514-99530.
612Sankar S et.al. (2017). Geminin deficiency enhances survival in a murine medulloblastoma model by inducing apoptosis of preneoplastic granule neuron precursors. Genes Cancer 8:725-744.
611Mohlin S et.al. (2017). No reason to reconsider HIF-2 as an oncogene in neuroblastoma and other cancer forms. Proc Natl Acad Sci U S A 114:E10856-E10858.
610Garcia-Heredia JM et.al. (2017). The cargo protein MAP17 (PDZK1IP1) regulates the immune microenvironment. Oncotarget 8:98580-98597.
609Hou J et.al. (2017). Increased Jab1/COPS5 is associated with therapeutic response and adverse outcome in lung cancer and breast cancer patients. Oncotarget 8:97504-97515.
608Yuan ZS et.al. (2017). IGFBP2 induces SPRY1 expression via NF-kappaB signaling pathway in glioblastoma multiforme (GBM). Eur Rev Med Pharmacol Sci 21:5072-5080.
607Tummler C et.al. (2017). Inhibition of chemerin/CMKLR1 axis in neuroblastoma cells reduces clonogenicity and cell viability in vitro and impairs tumor growth in vivo. Oncotarget 8:95135-95151.
606Sun W et.al. (2017). EWS-FLI1 and RNA helicase A interaction inhibitor YK-4-279 inhibits growth of neuroblastoma. Oncotarget 8:94780-94792.
605Linares-Clemente P et.al. (2017). Neural crest derived progenitor cells contribute to tumor stroma and aggressiveness in stage 4/M neuroblastoma. Oncotarget 8:89775-89792.
604Villasante A et.al. (2017). Vascularized Tissue-Engineered Model for Studying Drug Resistance in Neuroblastoma. Theranostics 7:4099-4117.
603Jongen JMJ et.al. (2017). Downregulation of DNA repair proteins and increased DNA damage in hypoxic colon cancer cells is a therapeutically exploitable vulnerability. Oncotarget 8:86296-86311.
602Bustos V et.al. (2017). GPER mediates differential effects of estrogen on colon cancer cell proliferation and migration under normoxic and hypoxic conditions. Oncotarget 8:84258-84275.
601Paul P et.al. (2017). Elevated TIMP-1 expression is associated with a prometastatic phenotype, disease relapse, and poor survival in neuroblastoma. Oncotarget 8:82609-82620.
600Hurst CD et.al. (2017). Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency. Cancer Cell 32:701-715.e7.
599Savci-Heijink CD et.al. (2017). Association between gene expression profile of the primary tumor and chemotherapy response of metastatic breast cancer. BMC Cancer 17:755.
598Chang W et.al. (2017). Immature colon carcinoma transcript-1 promotes cell growth of hepatocellular carcinoma via facilitating cell cycle progression and apoptosis resistance. Oncol Rep 38:3489-3496.
597Zhang D et.al. (2017). Down-regulation of CHERP inhibits neuroblastoma cell proliferation and induces apoptosis through ER stress induction. Oncotarget 8:80956-80970.
596Mir SE et.al. (2017). Trimethylation of H3K27 during human cerebellar development in relation to medulloblastoma. Oncotarget 8:78978-78988.
595Zhou G et.al. (2017). Homeobox B4 inhibits breast cancer cell migration by directly binding to StAR-related lipid transfer domain protein 13. Oncol Lett 14:4625-4632.
594Hong L et.al. (2017). Downregulation of miR-16 via URGCP pathway contributes to glioma growth. Sci Rep 7:13470.
593Yang Z et.al. (2017). Reprogramming of stromal fibroblasts by SNAI2 contributes to tumor desmoplasia and ovarian cancer progression. Mol Cancer 16:163.
592Xu L et.al. (2017). YBX1 promotes tumor growth by elevating glycolysis in human bladder cancer. Oncotarget 8:65946-65956.
591Delloye-Bourgeois C et.al. (2017). Microenvironment-Driven Shift of Cohesion/Detachment Balance within Tumors Induces a Switch toward Metastasis in Neuroblastoma. Cancer Cell 32:427-443.e8.
590Tao Y et.al. (2017). miR-205 regulation of ICT1 has an oncogenic potential via promoting the migration and invasion of gastric cancer cells. Biomed Pharmacother 96:191-197.
589Mahmud H et.al. (2017). Peptide microarray profiling identifies phospholipase C gamma 1 (PLC-gamma1) as a potential target for t(8;21) AML. Oncotarget 8:67344-67354.
588Lobbardi R et.al. (2017). TOX Regulates Growth, DNA Repair, and Genomic Instability in T-cell Acute Lymphoblastic Leukemia. Cancer Discov 7:1336-1353.
587van Attekum MHA et.al. (2017). CD40 signaling instructs chronic lymphocytic leukemia cells to attract monocytes via the CCR2 axis. Haematologica 102:2069-2076.
586Vardon A et.al. (2017). Arginine auxotrophic gene signature in paediatric sarcomas and brain tumours provides a viable target for arginine depletion therapies. Oncotarget 8:63506-63517.
585Kumar SS et.al. (2017). BMI-1 is a potential therapeutic target in diffuse intrinsic pontine glioma. Oncotarget 8:62962-62975.
584Russo R et.al. (2017). Kinome expression profiling of human neuroblastoma tumors identifies potential drug targets for ultra high-risk patients. Carcinogenesis 38:1011-1020.
583Kumar SA et.al. (2017). Pathological and prognostic role of mdig in pancreatic cancer. Genes Cancer 8:650-658.
582Meel MH et.al. (2017). Culture methods of diffuse intrinsic pontine glioma cells determine response to targeted therapies. Exp Cell Res 360:397-403.
581Yue C et.al. (2017). High expression of Brutons tyrosine kinase (BTK) is required for EGFR-induced NF-kappaB activation and predicts poor prognosis in human glioma. J Exp Clin Cancer Res 36:132.
580Wu X et.al. (2017). Extra-mitochondrial prosurvival BCL-2 proteins regulate gene transcription by inhibiting the SUFU tumour suppressor. Nat Cell Biol 19:1226-1236.
579Guadagno E et.al. (2017). PATZ1 is a new prognostic marker of glioblastoma associated with the stem-like phenotype and enriched in the proneural subtype. Oncotarget 8:59282-59300.
578Canovas V et.al. (2017). Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells. Oncotarget 8:59165-59180.
577Jimenez-Garcia MP et.al. (2017). Inflammation and stem markers association to PIM1/PIM2 kinase-induced tumors in breast and uterus. Oncotarget 8:58872-58886.
576Wang S et.al. (2017). BMPR2 promotes invasion and metastasis via the RhoA-ROCK-LIMK2 pathway in human osteosarcoma cells. Oncotarget 8:58625-58641.
575Villa E et.al. (2017). Parkin-Independent Mitophagy Controls Chemotherapeutic Response in Cancer Cells. Cell Rep 20:2846-2859.
574Li Y et.al. (2017). Genomic analysis-integrated whole-exome sequencing of neuroblastomas identifies genetic mutations in axon guidance pathway. Oncotarget 8:56684-56697.
573Bosse KR et.al. (2017). Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. Cancer Cell 32:295-309.e12.
572Erdreich-Epstein A et.al. (2017). Association of high microvessel alphavbeta3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. Oncotarget 8:52193-52210.
571Strobel T et.al. (2017). Ape1 guides DNA repair pathway choice that is associated with drug tolerance in glioblastoma. Sci Rep 7:9674.
570Ryl T et.al. (2017). Cell-Cycle Position of Single MYC-Driven Cancer Cells Dictates Their Susceptibility to a Chemotherapeutic Drug. Cell Syst 5:237-250.e8.
569Bingel C et.al. (2017). Three-dimensional tumor cell growth stimulates autophagic flux and recapitulates chemotherapy resistance. Cell Death Dis 8:e3013.
568Jeanne A et.al. (2017). Lumican delays melanoma growth in mice and drives tumor molecular assembly as well as response to matrix-targeted TAX2 therapeutic peptide. Sci Rep 7:7700.
567Li Y et.al. (2017). CircHIPK3 sponges miR-558 to suppress heparanase expression in bladder cancer cells. EMBO Rep 18:1646-1659.
566Watanabe Y et.al. (2017). ZAR1 knockdown promotes the differentiation of human neuroblastoma cells by suppression of MYCN expression. Med Oncol 34:158.
565Ambrosio S et.al. (2017). Lysine-specific demethylase LSD1 regulates autophagy in neuroblastoma through SESN2-dependent pathway. Oncogene 36:6701-6711.
564Calero R et.al. (2017). Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma. Cancer Lett 406:1-11.
563Roy R et.al. (2017). ADAM12 Is a Novel Regulator of Tumor Angiogenesis via STAT3 Signaling. Mol Cancer Res 15:1608-1622.
562Xie Y et.al. (2017). Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma. Gastroenterology 153:1429-1443.e5.
561Bloemendaal FM et.al. (2017). Anti-Tumor Necrosis Factor With a Glyco-Engineered Fc-Region Has Increased Efficacy in Mice With Colitis. Gastroenterology 153:1351-1362.e4.
560Satterfield L et.al. (2017). miR-130b directly targets ARHGAP1 to drive activation of a metastatic CDC42-PAK1-AP1 positive feedback loop in Ewing sarcoma. Int J Cancer 141:2062-2075.
559Vellinga TT et.al. (2017). Lymphangiogenic Gene Expression Is Associated With Lymph Node Recurrence and Poor Prognosis After Partial Hepatectomy for Colorectal Liver Metastasis. Ann Surg 266:765-771.
558Li N et.al. (2017). Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma. Proc Natl Acad Sci U S A 114:E6623-E6631.
557Dyberg C et.al. (2017). Rho-associated kinase is a therapeutic target in neuroblastoma. Proc Natl Acad Sci U S A 114:E6603-E6612.
556Brauss TF et.al. (2017). The RNA-binding protein HuR inhibits expression of CCL5 and limits recruitment of macrophages into tumors. Mol Carcinog 56:2620-2629.
555Northcott PA et.al. (2017). The whole-genome landscape of medulloblastoma subtypes. Nature 547:311-317.
554Wang Y et.al. (2017). Long non-coding RNA CASC2 suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells through CASC2/miR-367/FBXW7 axis. Mol Cancer 16:123.
553Park NI et.al. (2017). ASCL1 Reorganizes Chromatin to Direct Neuronal Fate and Suppress Tumorigenicity of Glioblastoma Stem Cells. Cell Stem Cell 21:209-224.e7.
552Westerlund I et.al. (2017). Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2alpha to tumor suppression. Proc Natl Acad Sci U S A 114:E6137-E6146.
551Friedrich C et.al. (2017). Tropomyosin receptor kinase C (TrkC) expression in medulloblastoma: relation to the molecular subgroups and impact on treatment response. Childs Nerv Syst 33:1463-1471.
550Trumpi K et.al. (2017). Neoadjuvant chemotherapy affects molecular classification of colorectal tumors. Oncogenesis 6:e357.
549Neto M et.al. (2017). Nuclear receptors connect progenitor transcription factors to cell cycle control. Sci Rep 7:4845.
548Sun Y et.al. (2017). Upregulation of LYAR induces neuroblastoma cell proliferation and survival. Cell Death Differ 24:1645-1654.
547Ma X et.al. (2017). CXCR4 expression varies significantly among different subtypes of glioblastoma multiforme (GBM) and its low expression or hypermethylation might predict favorable overall survival. Expert Rev Neurother 17:941-946.
546Yang J et.al. (2017). Targeting Histone Demethylases in MYC-Driven Neuroblastomas with Ciclopirox. Cancer Res 77:4626-4638.
545Layer JP et.al. (2017). Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression. Oncoimmunology 6:e1320626.
544Lennicke C et.al. (2017). Modulation of MHC class I surface expression in B16F10 melanoma cells by methylseleninic acid. Oncoimmunology 6:e1259049.
543Capasso M et.al. (2017). The functional variant rs34330 of CDKN1B is associated with risk of neuroblastoma. J Cell Mol Med 21:3224-3230.
542van Groningen T et.al. (2017). Neuroblastoma is composed of two super-enhancer-associated differentiation states. Nat Genet 49:1261-1266.
541Conduit SE et.al. (2017). A compartmentalized phosphoinositide signaling axis at cilia is regulated by INPP5E to maintain cilia and promote Sonic Hedgehog medulloblastoma. Oncogene 36:5969-5984.
540Fell SM et.al. (2017). Neuroblast differentiation during development and in neuroblastoma requires KIF1Bbeta-mediated transport of TRKA. Genes Dev 31:1036-1053.
539Rodriguez-Hernandez G et.al. (2017). Infection Exposure Promotes ETV6-RUNX1 Precursor B-cell Leukemia via Impaired H3K4 Demethylases. Cancer Res 77:4365-4377.
538Chikaraishi K et.al. (2017). CFC1 is a cancer stemness-regulating factor in neuroblastoma. Oncotarget 8:45046-45059.
537de Rooij B et.al. (2017). Acute lymphoblastic leukemia cells create a leukemic niche without affecting the CXCR4/CXCL12 axis. Haematologica 102:e389-e393.
536Mu P et.al. (2017). A novel nuclear complex of DRR1, F-actin and COMMD1 involved in NF-kappaB degradation and cell growth suppression in neuroblastoma. Oncogene 36:5745-5756.
535Su YK et.al. (2017). Antrodia cinnamomea sensitizes radio-/chemo-therapy of cancer stem-like cells by modulating microRNA expression. J Ethnopharmacol 207:47-56.
534Gao S et.al. (2017). Overexpression of RASD1 inhibits glioma cell migration/invasion and inactivates the AKT/mTOR signaling pathway. Sci Rep 7:3202.
533Dong X et.al. (2017). RSPO2 suppresses colorectal cancer metastasis by counteracting the Wnt5a/Fzd7-driven noncanonical Wnt pathway. Cancer Lett 402:153-165.
532Seifert A et.al. (2017). Tightly controlled MRTF-A activity regulates epithelial differentiation during formation of mammary acini. Breast Cancer Res 19:68.
531Delaidelli A et.al. (2017). MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation. Cell Death Differ 24:1564-1576.
530Maciaczyk D et.al. (2017). CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells. Br J Cancer 117:102-112.
529Liu H et.al. (2017). MELK and EZH2 Cooperate to Regulate Medulloblastoma Cancer Stem-like Cell Proliferation and Differentiation. Mol Cancer Res 15:1275-1286.
528Stiegelbauer V et.al. (2017). miR-196b-5p Regulates Colorectal Cancer Cell Migration and Metastases through Interaction with HOXB7 and GALNT5. Clin Cancer Res 23:5255-5266.
527Kawauchi D et.al. (2017). Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells. Oncogene 36:5231-5242.
526Henssen AG et.al. (2017). PGBD5 promotes site-specific oncogenic mutations in human tumors. Nat Genet 49:1005-1014.
525Veenstra VL et.al. (2017). Stromal SPOCK1 supports invasive pancreatic cancer growth. Mol Oncol 11:1050-1064.
524Schmidt C et.al. (2017). Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients. Neuro Oncol 19:1607-1617.
523Silginer M et.al. (2017). Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastoma. Neuro Oncol 19:1338-1349.
522Chen NP et.al. (2017). Human phosphatase CDC14A regulates actin organization through dephosphorylation of epithelial protein lost in neoplasm. Proc Natl Acad Sci U S A 114:5201-5206.
521Roy A et.al. (2017). Serglycin as a potential biomarker for glioma: association of serglycin expression, extent of mast cell recruitment and glioblastoma progression. Oncotarget 8:24815-24827.
520Duong C et.al. (2017). Novel targeted therapy for neuroblastoma: silencing the MXD3 gene using siRNA. Pediatr Res 82:527-535.
519Sanden E et.al. (2017). Establishment and characterization of an orthotopic patient-derived Group 3 medulloblastoma model for preclinical drug evaluation. Sci Rep 7:46366.
518Yurugi H et.al. (2017). Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours. Oncogene 36:4778-4789.
517Kanska J et.al. (2017). Glucose deprivation elicits phenotypic plasticity via ZEB1-mediated expression of NNMT. Oncotarget 8:26200-26220.
516Pezzolo A et.al. (2017). Constitutional 3p26.3 terminal microdeletion in an adolescent with neuroblastoma. Cancer Biol Ther 18:285-289.
515Xu J et.al. (2017). PID1 increases chemotherapy-induced apoptosis in medulloblastoma and glioblastoma cells in a manner that involves NFkappaB. Sci Rep 7:835.
514Colicchia V et.al. (2017). PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma. Oncogene 36:4682-4691.
513Deivendran S et.al. (2017). Metastasis-associated protein 1 is an upstream regulator of DNMT3a and stimulator of insulin-growth factor binding protein-3 in breast cancer. Sci Rep 7:44225.
512Thompson EM et.al. (2017). The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival. Neuro Oncol 19:1217-1227.
511Seystahl K et.al. (2017). Biological Role and Therapeutic Targeting of TGF-beta3 in Glioblastoma. Mol Cancer Ther 16:1177-1186.
510Rapetti-Mauss R et.al. (2017). Bidirectional KCNQ1:beta-catenin interaction drives colorectal cancer cell differentiation. Proc Natl Acad Sci U S A 114:4159-4164.
509Pang Z et.al. (2017). Expressions of insulin-like growth factor receptor-1 and cezanne-1 in lung adenocarcinoma. Med Oncol 34:78.
508Bhatia S et.al. (2017). Combined EphB2 receptor knockdown with radiation decreases cell viability and invasion in medulloblastoma. Cancer Cell Int 17:41.
507Kaluski S et.al. (2017). Neuroprotective Functions for the Histone Deacetylase SIRT6. Cell Rep 18:3052-3062.
506Dewi DL et.al. (2017). Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer. Oncoimmunology 6:e1274477.
505Zhang S et.al. (2017). m(6)A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program. Cancer Cell 31:591-606.e6.
504Wang K et.al. (2017). The noncoding RNA linc-ADAMTS5 cooperates with RREB1 to protect from intervertebral disc degeneration through inhibiting ADAMTS5 expression. Clin Sci (Lond) 131:965-979.
503Guo P et.al. (2017). A quantitative method for screening and identifying molecular targets for nanomedicine. J Control Release 263:57-67.
502Zhang X et.al. (2017). Critical Role for GAB2 in Neuroblastoma Pathogenesis through the Promotion of SHP2/MYCN Cooperation. Cell Rep 18:2932-2942.
501Thewes V et.al. (2017). The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ERalpha-negative breast cancer. Oncogene 36:4124-4134.
500Raats DA et.al. (2017). CD95 ligand induces senescence in mismatch repair-deficient human colon cancer via chronic caspase-mediated induction of DNA damage. Cell Death Dis 8:e2669.
499Zhang D et.al. (2017). ALG2 regulates glioblastoma cell proliferation, migration and tumorigenicity. Biochem Biophys Res Commun 486:300-306.
498Gholamin S et.al. (2017). Disrupting the CD47-SIRPalpha anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. Sci Transl Med 9:.
497Sewing ACP et.al. (2017). Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma. J Neurosurg Pediatr 19:518-530.
496Zhou F et.al. (2017). Jab1/Csn5-Thioredoxin Signaling in Relapsed Acute Monocytic Leukemia under Oxidative Stress. Clin Cancer Res 23:4450-4461.
495Tao T et.al. (2017). The pre-rRNA processing factor DEF is rate limiting for the pathogenesis of MYCN-driven neuroblastoma. Oncogene 36:3852-3867.
494Abbasi MR et.al. (2017). Impact of Disseminated Neuroblastoma Cells on the Identification of the Relapse-Seeding Clone. Clin Cancer Res 23:4224-4232.
493An T et.al. (2017). USP7 inhibitor P5091 inhibits Wnt signaling and colorectal tumor growth. Biochem Pharmacol 131:29-39.
492Bate-Eya LT et.al. (2017). Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity. Eur J Cancer 75:63-72.
491Wong M et.al. (2017). The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription. Cancer Res 77:2522-2533.
490Tu Y et.al. (2017). Smoothened is a poor prognosis factor and a potential therapeutic target in glioma. Sci Rep 7:42630.
489Bi G et.al. (2017). PRRT2 inhibits the proliferation of glioma cells by modulating unfolded protein response pathway. Biochem Biophys Res Commun 485:454-460.
488Cheng F et.al. (2017). RNA-Binding Protein Dnd1 Promotes Breast Cancer Apoptosis by Stabilizing the Bim mRNA in a miR-221 Binding Site. Biomed Res Int 2017:9596152.
487Duffy DJ et.al. (2017). Retinoic acid and TGF-beta signalling cooperate to overcome MYCN-induced retinoid resistance. Genome Med 9:15.
486Gaviglio AL et.al. (2017). Heparin-binding epidermal growth factor-like growth factor promotes neuroblastoma differentiation. FASEB J 31:1903-1915.
485Lin C et.al. (2017). Potential importance of protease activated receptor (PAR)-1 expression in the tumor stroma of non-small-cell lung cancer. BMC Cancer 17:113.
484Kakumu T et.al. (2017). Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer. Cancer Sci 108:732-743.
483Garcia-Heredia JM et.al. (2017). The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB. Clin Cancer Res 23:3871-3883.
482Chanakira A et.al. (2017). Tissue factor-factor VIIa complex triggers protease activated receptor 2-dependent growth factor release and migration in ovarian cancer. Gynecol Oncol 145:167-175.
481Wang D et.al. (2017). Aberrant activation of hedgehog signaling promotes cell proliferation via the transcriptional activation of forkhead Box M1 in colorectal cancer cells. J Exp Clin Cancer Res 36:23.
480Fancello L et.al. (2017). The ribosomal protein gene RPL5 is a haploinsufficient tumor suppressor in multiple cancer types. Oncotarget 8:14462-14478.
479Chung ST et.al. (2017). Osteoprotegerin mediates tumor-promoting effects of Interleukin-1beta in breast cancer cells. Mol Cancer 16:27.
478Carpi S et.al. (2017). Tumor-promoting effects of cannabinoid receptor type 1 in human melanoma cells. Toxicol In Vitro 40:272-279.
477Xu M et.al. (2017). Interactions between interleukin-6 and myeloid-derived suppressor cells drive the chemoresistant phenotype of hepatocellular cancer. Exp Cell Res 351:142-149.
476Jeibmann A et.al. (2017). SMAD dependent signaling plays a detrimental role in a fly model of SMARCB1-deficiency and the biology of atypical teratoid/rhabdoid tumors. J Neurooncol 131:477-484.
475Veschi V et.al. (2017). Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma. Cancer Cell 31:50-63.
474Baglio SR et.al. (2017). Blocking Tumor-Educated MSC Paracrine Activity Halts Osteosarcoma Progression. Clin Cancer Res 23:3721-3733.
473Busiello T et.al. (2017). Role of ZNF224 in cell growth and chemoresistance of chronic lymphocitic leukemia. Hum Mol Genet 26:344-353.
472Villanueva AA et.al. (2017). The Netrin-4/ Neogenin-1 axis promotes neuroblastoma cell survival and migration. Oncotarget 8:9767-9782.
471El-Habr EA et.al. (2017). A driver role for GABA metabolism in controlling stem and proliferative cell state through GHB production in glioma. Acta Neuropathol 133:645-660.
470Jung M et.al. (2017). A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers. Cancer Res 77:971-981.
469Hofman IJF et.al. (2017). RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response. Leukemia 31:1706-1714.
468van Keimpema M et.al. (2017). The small FOXP1 isoform predominantly expressed in activated B cell-like diffuse large B-cell lymphoma and full-length FOXP1 exert similar oncogenic and transcriptional activity in human B cells. Haematologica 102:573-583.
467Bieerkehazhi S et.al. (2017). Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling. Oncotarget 8:1469-1480.
466Mao X et.al. (2017). Novel multi-targeted ErbB family inhibitor afatinib blocks EGF-induced signaling and induces apoptosis in neuroblastoma. Oncotarget 8:1555-1568.
465Seong BK et.al. (2017). A Metastatic Mouse Model Identifies Genes That Regulate Neuroblastoma Metastasis. Cancer Res 77:696-706.
464Ambrosio S et.al. (2017). LSD1 mediates MYCN control of epithelial-mesenchymal transition through silencing of metastatic suppressor NDRG1 gene. Oncotarget 8:3854-3869.
463Charlet J et.al. (2017). Genome-wide DNA methylation analysis identifies MEGF10 as a novel epigenetically repressed candidate tumor suppressor gene in neuroblastoma. Mol Carcinog 56:1290-1301.
462Zhang H et.al. (2017). STARD13 promotes hepatocellular carcinoma apoptosis by acting as a ceRNA for Fas. Biotechnol Lett 39:207-217.
461Jeanne A et.al. (2017). Thrombospondin-targeting TAX2 peptide impairs tumor growth in preclinical mouse models of childhood neuroblastoma. Pediatr Res 81:480-488.
460McManus M et.al. (2017). Hes4: A potential prognostic biomarker for newly diagnosed patients with high-grade osteosarcoma. Pediatr Blood Cancer 64:.
459Xiong N et.al. (2017). Involvement of caveolin-1 in low shear stress-induced breast cancer cell motility and adhesion: Roles of FAK/Src and ROCK/p-MLC pathways. Biochim Biophys Acta 1864:12-22.
458Jan A et.al. (2017). eEF2K inhibition blocks Abeta42 neurotoxicity by promoting an NRF2 antioxidant response. Acta Neuropathol 133:101-119.
457Borovski T et.al. (2017). Inhibition of RAF1 kinase activity restores apicobasal polarity and impairs tumour growth in human colorectal cancer. Gut 66:1106-1115.
456Hou J et.al. (2017). CSN6 controls the proliferation and metastasis of glioblastoma by CHIP-mediated degradation of EGFR. Oncogene 36:1134-1144.
455Pan Y et.al. (2017). Stat3 contributes to cancer progression by regulating Jab1/Csn5 expression. Oncogene 36:1069-1079.
454Huang MY et.al. (2017). MINA controls proliferation and tumorigenesis of glioblastoma by epigenetically regulating cyclins and CDKs via H3K9me3 demethylation. Oncogene 36:387-396.
453Li C et.al. (2017). Elevated AQP1 Expression Is Associated With Unfavorable Oncologic Outcome in Patients With Hilar Cholangiocarcinoma. Technol Cancer Res Treat 16:421-427.
2016 (n=142)
452Hansen JN et.al. (2016). EYA1 expression and subcellular localization in neuroblastoma and its association with prognostic markers. J Cancer Res Ther (Manch) 4:11-18.
451Cangelosi D et.al. (2016). Artificial neural network classifier predicts neuroblastoma patients outcome. BMC Bioinformatics 17:347.
450Eissler N et.al. (2016). Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade. Oncoimmunology 5:e1232222.
449Kasim M et.al. (2016). Achaete-Scute Homolog 1 Expression Controls Cellular Differentiation of Neuroblastoma. Front Mol Neurosci 9:156.
448Salazar BM et.al. (2016). Neuroblastoma, a Paradigm for Big Data Science in Pediatric Oncology. Int J Mol Sci 18:.
447Mooberry LK et.al. (2016). Targeting the SR-B1 Receptor as a Gateway for Cancer Therapy and Imaging. Front Pharmacol 7:466.
446Chen Z et.al. (2016). Wip1 inhibitor GSK2830371 inhibits neuroblastoma growth by inducing Chk2/p53-mediated apoptosis. Sci Rep 6:38011.
445Ma W et.al. (2016). Human Papillomavirus Downregulates the Expression of IFITM1 and RIPK3 to Escape from IFNgamma Front Immunol 7:496.
444Jimenez-Garcia MP et.al. (2016). The role of PIM1/PIM2 kinases in tumors of the male reproductive system. Sci Rep 6:38079.
443Vella S et.al. (2016). Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells. PLoS One 11:e0166233.
442Gao S et.al. (2016). Low Expression of CAPON in Glioma Contributes to Cell Proliferation via the Akt Signaling Pathway. Int J Mol Sci 17:.
441den Uil SH et.al. (2016). Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrence. Br J Cancer 115:1565-1574.
440Qiu X et.al. (2016). Overexpression of FZD7 promotes glioma cell proliferation by upregulating TAZ. Oncotarget 7:85987-85999.
439Augustin I et.al. (2016). Immune cell recruitment in teratomas is impaired by increased Wnt secretion. Stem Cell Res 17:607-615.
438Stankovic ND et.al. (2016). No role of IFITM3 in brain tumor formation in vivo. Oncotarget 7:86388-86405.
437Maugeri M et.al. (2016). Altered expression of miRNAs and methylation of their promoters are correlated in neuroblastoma. Oncotarget 7:83330-83341.
436Sulzmaier FJ et.al. (2016). RSK2 activity mediates glioblastoma invasiveness and is a potential target for new therapeutics. Oncotarget 7:79869-79884.
435Bassett EA et.al. (2016). Norrin/Frizzled4 signalling in the preneoplastic niche blocks medulloblastoma initiation. Elife 5:.
434Techavichit P et.al. (2016). Secreted Frizzled-Related Protein 2 (sFRP2) promotes osteosarcoma invasion and metastatic potential. BMC Cancer 16:869.
433Trypsteen W et.al. (2016). Differential expression of lncRNAs during the HIV replication cycle: an underestimated layer in the HIV-host interplay. Sci Rep 6:36111.
432Xiao D et.al. (2016). Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival. Mol Cell 64:493-506.
431Zhao Z et.al. (2016). A combined gene expression and functional study reveals the crosstalk between N-Myc and differentiation-inducing microRNAs in neuroblastoma cells. Oncotarget 7:79372-79387.
430Liu PY et.al. (2016). NCYM is upregulated by lncUSMycN and modulates N-Myc expression. Int J Oncol 49:2464-2470.
429Liu X et.al. (2016). CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways. J Hematol Oncol 9:108.
428Flahaut M et.al. (2016). Aldehyde dehydrogenase activity plays a Key role in the aggressive phenotype of neuroblastoma. BMC Cancer 16:781.
427Zhang H et.al. (2016). Expression and significance of Hippo/YAP signaling in glioma progression. Tumour Biol :.
426Liu M et.al. (2016). Transcriptional Profiling Reveals a Common Metabolic Program in High-Risk Human Neuroblastoma and Mouse Neuroblastoma Sphere-Forming Cells. Cell Rep 17:609-623.
425Matas-Rico E et.al. (2016). Glycerophosphodiesterase GDE2 Promotes Neuroblastoma Differentiation through Glypican Release and Is a Marker of Clinical Outcome. Cancer Cell 30:548-562.
424Catena V et.al. (2016). Deptor transcriptionally regulates endoplasmic reticulum homeostasis in multiple myeloma cells. Oncotarget 7:70546-70558.
423Brand A et.al. (2016). LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. Cell Metab 24:657-671.
422Henrich KO et.al. (2016). Integrative Genome-Scale Analysis Identifies Epigenetic Mechanisms of Transcriptional Deregulation in Unfavorable Neuroblastomas. Cancer Res 76:5523-37.
421Wang LY et.al. (2016). KDM4A Coactivates E2F1 to Regulate the PDK-Dependent Metabolic Switch between Mitochondrial Oxidation and Glycolysis. Cell Rep 16:3016-3027.
420Suryo Rahmanto A et.al. (2016). FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma. EMBO J 35:2192-2212.
419Tavana O et.al. (2016). HAUSP deubiquitinates and stabilizes N-Myc in neuroblastoma. Nat Med 22:1180-1186.
418Garcia-Heredia JM et.al. (2016). Numb-like (NumbL) downregulation increases tumorigenicity, cancer stem cell-like properties and resistance to chemotherapy. Oncotarget 7:63611-63628.
417Ubink I et.al. (2016). A potential role for CCN2/CTGF in aggressive colorectal cancer. J Cell Commun Signal 10:223-227.
416Jia D et.al. (2016). A COL11A1-correlated pan-cancer gene signature of activated fibroblasts for the prioritization of therapeutic targets. Cancer Lett 382:203-214.
415Cimmino F et.al. (2016). Proteomic Alterations in Response to Hypoxia Inducible Factor 2alpha in Normoxic Neuroblastoma Cells. J Proteome Res 15:3643-3655.
414Qu H et.al. (2016). Smad4 suppresses the tumorigenesis and aggressiveness of neuroblastoma through repressing the expression of heparanase. Sci Rep 6:32628.
413Chakrabarti A et.al. (2016). Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseases. Future Med Chem 8:1609-34.
412Fabian J et.al. (2016). MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma. Oncotarget 7:66344-66359.
411Eberhardt A et.al. (2016). Protein arginine methyltransferase 1 is a novel regulator of MYCN in neuroblastoma. Oncotarget 7:63629-63639.
410Wang Z et.al. (2016). CD151-mediated adhesion is crucial to osteosarcoma pulmonary metastasis. Oncotarget 7:60623-60638.
409Murakami-Tonami Y et.al. (2016). SGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells. Sci Rep 6:31615.
408Montalban Del Barrio I et.al. (2016). Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages J Immunother Cancer 4:49.
407Duffy DJ et.al. (2016). Wnt signalling is a bi-directional vulnerability of cancer cells. Oncotarget 7:60310-60331.
406Buren S et.al. (2016). Regulation of OGT by URI in Response to Glucose Confers c-MYC-Dependent Survival Mechanisms. Cancer Cell 30:290-307.
405Franco R et.al. (2016). PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas. Oncotarget 7:59158-59172.
404Worst BC et.al. (2016). Next-generation personalised medicine for high-risk paediatric cancer patients Eur J Cancer 65:91-101.
403Kritikou JS et.al. (2016). IL-2 in the tumor microenvironment is necessary for Wiskott-Aldrich syndrome protein deficient NK cells to respond to tumors in vivo. Sci Rep 6:30636.
402Lu F et.al. (2016). Downregulation of CREB Promotes Cell Proliferation by Mediating G1/S Phase Transition in Hodgkin Lymphoma. Oncol Res 24:171-9.
401Prince EW et.al. (2016). Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma. Oncotarget 7:53881-53894.
400Snapkov I et.al. (2016). The role of formyl peptide receptor 1 (FPR1) in neuroblastoma tumorigenesis. BMC Cancer 16:490.
399Thimsen V et.al. (2016). EpCAM (CD326) is differentially expressed in craniopharyngioma subtypes and Rathkes cleft cysts. Sci Rep 6:29731.
398Madan M et.al. (2016). ATP13A3 and caveolin-1 as potential biomarkers for difluoromethylornithine-based therapies in pancreatic cancers. Am J Cancer Res 6:1231-52.
397van Engen CE et.al. (2016). CYP4F2 affects phenotypic outcome in adrenoleukodystrophy by modulating the clearance of very long-chain fatty acids. Biochim Biophys Acta 1862:1861-70.
396Somarelli JA et.al. (2016). Mesenchymal-Epithelial Transition in Sarcomas Is Controlled by the Combinatorial Expression of MicroRNA 200s and GRHL2. Mol Cell Biol 36:2503-13.
395Middelbeek J et.al. (2016). The TRPM7 interactome defines a cytoskeletal complex linked to neuroblastoma progression. Eur J Cell Biol 95:465-474.
394Powers JT et.al. (2016). Multiple mechanisms disrupt the let-7 microRNA family in neuroblastoma. Nature 535:246-51.
393Taminiau A et.al. (2016). HOXA1 binds RBCK1/HOIL-1 and TRAF2 and modulates the TNF/NF-kappaB pathway in a transcription-independent manner. Nucleic Acids Res 44:7331-49.
392Chen Z et.al. (2016). Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity. Sci Rep 6:29090.
391Sheikh A et.al. (2016). Unfavorable neuroblastoma prognostic factor NLRR2 inhibits cell differentiation by transcriptional induction through JNK pathway. Cancer Sci 107:1223-32.
390Gramatzki D et.al. (2016). Interleukin-33 in human gliomas: Expression and prognostic significance. Oncol Lett 12:445-452.
389Wang Y et.al. (2016). TP53INP1 3-UTR functions as a ceRNA in repressing the metastasis of glioma cells by regulating miRNA activity. Biotechnol Lett 38:1699-707.
388Jansen MH et.al. (2016). Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor Models. Mol Cancer Ther 15:2166-74.
387Agnihotri S et.al. (2016). PINK1 Is a Negative Regulator of Growth and the Warburg Effect in Glioblastoma. Cancer Res 76:4708-19.
386Joosten M et.al. (2016). A novel approach to detect resistance mechanisms reveals FGR as a factor mediating HDAC inhibitor SAHA resistance in B-cell lymphoma. Mol Oncol 10:1232-44.
385Shackleford GM et.al. (2016). BarTeL, a Genetically Versatile, Bioluminescent and Granule Neuron Precursor-Targeted Mouse Model for Medulloblastoma. PLoS One 11:e0156907.
384Phillips E et.al. (2016). Targeting atypical protein kinase C iota reduces viability in glioblastoma stem-like cells via a notch signaling mechanism. Int J Cancer 139:1776-87.
383Blaeschke F et.al. (2016). Human HLA-A*02:01/CHM1+ allo-restricted T cell receptor transgenic CD8+ T cells specifically inhibit Ewing sarcoma growth in vitro and in vivo. Oncotarget 7:43267-43280.
382Villasante A et.al. (2016). Recapitulating the Size and Cargo of Tumor Exosomes in a Tissue-Engineered Model. Theranostics 6:1119-30.
381Qu H et.al. (2016). microRNA-558 facilitates the expression of hypoxia-inducible factor 2 alpha through binding to 5-untranslated region in neuroblastoma. Oncotarget 7:40657-40673.
380Garcia-Ramirez I et.al. (2016). Could Vitamin D Analogues Be Used to Target Leukemia Stem Cells? Int J Mol Sci 17:.
379Han X et.al. (2016). Microfluidic Cell Deformability Assay for Rapid and Efficient Kinase Screening with the CRISPR-Cas9 System. Angew Chem Int Ed Engl 55:8561-5.
378Yogev O et.al. (2016). p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance. Cancer Res 76:3025-35.
377Formicola D et.al. (2016). An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma. J Transl Med 14:142.
376Faouzi M et.al. (2016). Functional cooperation between KCa3.1 and TRPC1 channels in human breast cancer: Role in cell proliferation and patient prognosis. Oncotarget 7:36419-36435.
375Fletcher JI et.al. (2016). ABC transporters as mediators of drug resistance and contributors to cancer cell biology. Drug Resist Updat 26:1-9.
374Folgiero V et.al. (2016). IDO1 involvement in mTOR pathway: a molecular mechanism of resistance to mTOR targeting in medulloblastoma. Oncotarget 7:52900-52911.
373Hsu CL et.al. (2016). Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data. Oncotarget 7:36293-36310.
372Yang R et.al. (2016). The Hippo transducer TAZ promotes cell proliferation and tumor formation of glioblastoma cells through EGFR pathway. Oncotarget 7:36255-36265.
371Berlanga P et.al. (2016). miR-200c and phospho-AKT as prognostic factors and mediators of osteosarcoma progression and lung metastasis. Mol Oncol 10:1043-53.
370Weeks A et.al. (2016). Epithelial Cell Transforming 2 and Aurora Kinase B Modulate Formation of Stress Granule-Containing Transcripts from Diverse Cellular Pathways in Astrocytoma Cells. Am J Pathol 186:1674-87.
369Fuady JH et.al. (2016). Estrogen-dependent downregulation of hypoxia-inducible factor (HIF)-2alpha in invasive breast cancer cells. Oncotarget 7:31153-65.
368Bate-Eya LT et.al. (2016). High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition. Oncotarget 7:27946-58.
367Kloepper J et.al. (2016). Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci U S A 113:4476-81.
366Cimmino F et.al. (2016). CD55 is a HIF-2alpha marker with anti-adhesive and pro-invading properties in neuroblastoma. Oncogenesis 5:e212.
365Dyberg C et.al. (2016). Planar cell polarity gene expression correlates with tumor cell viability and prognostic outcome in neuroblastoma. BMC Cancer 16:259.
364Woodfield SE et.al. (2016). Neuroblastoma patient outcomes, tumor differentiation, and ERK activation are correlated with expression levels of the ubiquitin ligase UBE4B. Genes Cancer 7:13-26.
363Lasorsa VA et.al. (2016). Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression. Oncotarget 7:21840-52.
362Szabo E et.al. (2016). Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo. Neuro Oncol 18:1242-52.
361Vellinga TT et.al. (2016). Collagen-rich stroma in aggressive colon tumors induces mesenchymal gene expression and tumor cell invasion. Oncogene 35:5263-5271.
360Agarwal S et.al. (2016). Transmembrane adaptor protein PAG1 is a novel tumor suppressor in neuroblastoma. Oncotarget 7:24018-26.
359Casey SC et.al. (2016). MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352:227-31.
358Savci-Heijink CD et.al. (2016). A novel gene expression signature for bone metastasis in breast carcinomas. Breast Cancer Res Treat 156:249-59.
357Aykul S et.al. (2016). Transforming Growth Factor-beta Family Ligands Can Function as Antagonists by Competing for Type II Receptor Binding. J Biol Chem 291:10792-804.
356Mao Y et.al. (2016). Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma. Clin Cancer Res 22:3849-59.
355Dondero A et.al. (2016). PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance. Oncoimmunology 5:e1064578.
354Lee D et.al. (2016). Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancy. J Clin Invest 126:1300-10.
353Holsken A et.al. (2016). Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles. Acta Neuropathol Commun 4:20.
352Woodfield SE et.al. (2016). Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression. BMC Cancer 16:172.
351Johann PD et.al. (2016). Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. Cancer Cell 29:379-393.
350Panosyan EH et.al. (2016). Clinical aggressiveness of malignant gliomas is linked to augmented metabolism of amino acids. J Neurooncol 128:57-66.
349Sturm D et.al. (2016). New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell 164:1060-1072.
348Bijnsdorp IV et.al. (2016). miR-129-3p controls centrosome number in metastatic prostate cancer cells by repressing CP110. Oncotarget 7:16676-87.
347Busch B et.al. (2016). The oncogenic triangle of HMGA2, LIN28B and IGF2BP1 antagonizes tumor-suppressive actions of the let-7 family. Nucleic Acids Res 44:3845-64.
346Yang L et.al. (2016). PHOX2B Is Associated with Neuroblastoma Cell Differentiation. Cancer Biother Radiopharm 31:44-51.
345Huang S et.al. (2016). Impact of S100A4 Expression on Clinicopathological Characteristics and Prognosis in Pancreatic Cancer: A Meta-Analysis. Dis Markers 2016:8137378.
344Kim PY et.al. (2016). High TDP43 expression is required for TRIM16-induced inhibition of cancer cell growth and correlated with good prognosis of neuroblastoma and breast cancer patients. Cancer Lett 374:315-23.
343Stojcheva N et.al. (2016). MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM. Oncotarget 7:12937-50.
342Abbou S et.al. (2016). Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies. Anticancer Res 36:599-609.
341Tetteh PW et.al. (2016). Replacement of Lost Lgr5-Positive Stem Cells through Plasticity of Their Enterocyte-Lineage Daughters. Cell Stem Cell 18:203-13.
340Soriano A et.al. (2016). MicroRNA-497 impairs the growth of chemoresistant neuroblastoma cells by targeting cell cycle, survival and vascular permeability genes. Oncotarget 7:9271-87.
339Li S et.al. (2016). The 1p36 Tumor Suppressor KIF 1Bbeta Is Required for Calcineurin Activation, Controlling Mitochondrial Fission and Apoptosis. Dev Cell 36:164-78.
338Olsson M et.al. (2016). Genome-wide methylation profiling identifies novel methylated genes in neuroblastoma tumors. Epigenetics 11:74-84.
337Morrissy AS et.al. (2016). Divergent clonal selection dominates medulloblastoma at recurrence. Nature 529:351-7.
336Sanchez-Osuna M et.al. (2016). An intrinsic DFF40/CAD endonuclease deficiency impairs oligonucleosomal DNA hydrolysis during caspase-dependent cell death: a common trait in human glioblastoma cells. Neuro Oncol 18:950-61.
335Than BL et.al. (2016). CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene 35:4179-87.
334Chen NP et.al. (2016). Human phosphatase CDC14A is recruited to the cell leading edge to regulate cell migration and adhesion. Proc Natl Acad Sci U S A 113:990-5.
333Codo P et.al. (2016). Control of glioma cell migration and invasiveness by GDF-15. Oncotarget 7:7732-46.
332Flori M et.al. (2016). The hematopoietic oncoprotein FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling. Blood 127:1438-48.
331Dey A et.al. (2016). YB-1 is elevated in medulloblastoma and drives proliferation in Sonic hedgehog-dependent cerebellar granule neuron progenitor cells and medulloblastoma cells. Oncogene 35:4256-68.
330Beach JA et.al. (2016). Sphingosine kinase 1 is required for TGF-beta mediated fibroblastto Oncotarget 7:4167-82.
329Roth SA et.al. (2016). Next generation sequencing of microRNAs from isogenic neuroblastoma cell lines isolated before and after treatment. Cancer Lett 372:128-36.
328Ochs K et.al. (2016). Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4. J Neurochem 136:1142-1154.
327Bedekovics T et.al. (2016). UCH-L1 is induced in germinal center B cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma. Blood 127:1564-74.
326DAsti E et.al. (2016). Tissue Factor Regulation by miR-520g in Primitive Neuronal Brain Tumor Cells: A Possible Link between Oncomirs and the Vascular Tumor Microenvironment. Am J Pathol 186:446-59.
325Shen B et.al. (2016). Upregulated SMYD3 promotes bladder cancer progression by targeting BCLAF1 and activating autophagy. Tumour Biol 37:7371-81.
324Henssen A et.al. (2016). Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition. Clin Cancer Res 22:2470-81.
323Fest S et.al. (2016). Targeting of heme oxygenase-1 as a novel immune regulator of neuroblastoma. Int J Cancer 138:2030-42.
322Xuan F et.al. (2016). Homeobox C9 suppresses Beclin1-mediated autophagy in glioblastoma by directly inhibiting the transcription of death-associated protein kinase 1. Neuro Oncol 18:819-29.
321Martins-Neves SR et.al. (2016). Chemotherapy induces stemness in osteosarcoma cells through activation of Wnt/beta-catenin signaling. Cancer Lett 370:286-95.
320Zhao X et.al. (2016). CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression. Oncogene 35:3565-76.
319Silginer M et.al. (2016). The aryl hydrocarbon receptor links integrin signaling to the TGF-beta pathway. Oncogene 35:3260-71.
318Masserot C et.al. (2016). WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma. Mol Oncol 10:240-52.
317Jin Y et.al. (2016). Single nucleotide polymorphism rs11669203 in TGFBR3L is associated with the risk of neuroblastoma in a Chinese population. Tumour Biol 37:3739-47.
316Godin-Heymann N et.al. (2016). Tumour-suppression function of KLF12 through regulation of anoikis. Oncogene 35:3324-34.
315Guo ST et.al. (2016). INPP4B is an oncogenic regulator in human colon cancer. Oncogene 35:3049-61.
314Martins-Neves SR et.al. (2016). Osteosarcoma Stem Cells Have Active Wnt/beta-catenin and Overexpress SOX2 and KLF4. J Cell Physiol 231:876-86.
313Rad A et.al. (2016). Predicting the molecular role of MEIS1 in esophageal squamous cell carcinoma. Tumour Biol 37:1715-25.
312Rogers MA et.al. (2016). CITED4 gene silencing in colorectal cancer cells modulates adherens/tight junction gene expression and reduces cell proliferation. J Cancer Res Clin Oncol 142:225-37.
311Heim S et.al. (2016). Papillary Tumor of the Pineal Region: A Distinct Molecular Entity. Brain Pathol 26:199-205.
2015 (n=122)
310Dolman ME et.al. (2015). DNA-Dependent Protein Kinase As Molecular Target for Radiosensitization of Neuroblastoma Cells. PLoS One 10:e0145744.
309Forgham H et.al. (2015). Stem Cell Markers in Neuroblastoma-An Emerging Role for LGR5. Front Cell Dev Biol 3:77.
308Ordonez-Moran P et.al. (2015). HOXA5 Counteracts Stem Cell Traits by Inhibiting Wnt Signaling in Colorectal Cancer. Cancer Cell 28:815-829.
307Giachino C et.al. (2015). A Tumor Suppressor Function for Notch Signaling in Forebrain Tumor Subtypes. Cancer Cell 28:730-742.
306Wickstrom M et.al. (2015). Wnt/beta-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance. Nat Commun 6:8904.
305Carter DR et.al. (2015). Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma. Sci Transl Med 7:312ra176.
304Xiao D et.al. (2015). Myc promotes glutaminolysis in human neuroblastoma through direct activation of glutaminase 2. Oncotarget 6:40655-66.
303Best MG et.al. (2015). RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics. Cancer Cell 28:666-676.
302Valentijn LJ et.al. (2015). TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Nat Genet 47:1411-4.
301Vieira GC et.al. (2015). LGR5 regulates pro-survival MEK/ERK and proliferative Wnt/beta-catenin signalling in neuroblastoma. Oncotarget 6:40053-67.
300Trumpi K et.al. (2015). ABC-Transporter Expression Does Not Correlate with Response to Irinotecan in Patients with Metastatic Colorectal Cancer. J Cancer 6:1079-86.
299Hussain S et.al. (2015). UCHL1 is a biomarker of aggressive multiple myeloma required for disease progression. Oncotarget 6:40704-18.
298Bogen D et.al. (2015). Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma. Oncotarget 6:35247-62.
297Raman P et.al. (2015). FXYD5 is a Marker for Poor Prognosis and a Potential Driver for Metastasis in Ovarian Carcinomas. Cancer Inform 14:113-9.
296Sun Y et.al. (2015). WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma. Cancer Res 75:5143-54.
295Park SY et.al. (2015). Combinatorial TGF-beta attenuation with paclitaxel inhibits the epithelial-to-mesenchymal transition and breast cancer stem-like cells. Oncotarget 6:37526-43.
294Wielenga MCB et.al. (2015). ER-Stress-Induced Differentiation Sensitizes Colon Cancer Stem Cells to Chemotherapy. Cell Rep 13:489-494.
293Bergenfelz C et.al. (2015). S100A9 expressed in ER(-)PgR(-) breast cancers induces inflammatory cytokines and is associated with an impaired overall survival. Br J Cancer 113:1234-43.
292Mohlin S et.al. (2015). PI3K-mTORC2 but not PI3K-mTORC1 regulates transcription of HIF2A/EPAS1 and vascularization in neuroblastoma. Cancer Res 75:4617-28.
291Baranski Z et.al. (2015). Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin. Oncotarget 6:36113-25.
290Shchors K et.al. (2015). Dual Targeting of the Autophagic Regulatory Circuitry in Gliomas with Repurposed Drugs Elicits Cell-Lethal Autophagy and Therapeutic Benefit. Cancer Cell 28:456-471.
289Dassi E et.al. (2015). Translational compensation of genomic instability in neuroblastoma. Sci Rep 5:14364.
288Mehmeti M et.al. (2015). Expression of functional toll like receptor 4 in estrogen receptor/progesterone receptor-negative breast cancer. Breast Cancer Res 17:130.
287Fontebasso AM et.al. (2015). Non-random aneuploidy specifies subgroups of pilocytic astrocytoma and correlates with older age. Oncotarget 6:31844-56.
286Khan FH et.al. (2015). RD3 loss dictates high-risk aggressive neuroblastoma and poor clinical outcomes. Oncotarget 6:36522-34.
285Liu Z et.al. (2015). Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation. Gynecol Oncol 139:394-400.
284Li C et.al. (2015). Identification and characterization of ANO9 in stage II and III colorectal carcinoma. Oncotarget 6:29324-34.
283De Mariano M et.al. (2015). Identification of GALNT14 as a novel neuroblastoma predisposition gene. Oncotarget 6:26335-46.
282Bartolini A et.al. (2015). The Neuronal Pentraxin-2 Pathway Is an Unrecognized Target in Human Neuroblastoma, Which Also Offers Prognostic Value in Patients. Cancer Res 75:4265-71.
281Zheng Y et.al. (2015). FoxM1 transactivates PTTG1 and promotes colorectal cancer cell migration and invasion. BMC Med Genomics 8:49.
280Choe SC et.al. (2015). Autophagy capacity and sub-mitochondrial heterogeneity shape Bnip3-induced mitophagy regulation of apoptosis. Cell Commun Signal 13:37.
279Lee EJ et.al. (2015). Identification of Global DNA Methylation Signatures in Glioblastoma-Derived Cancer Stem Cells. J Genet Genomics 42:355-71.
278Ramani P et.al. (2015). High proliferation index, as determined by immunohistochemical expression of Aurora kinase B and geminin, indicates poor prognosis in neuroblastomas. Virchows Arch 467:319-27.
277Stigliani S et.al. (2015). Expression of FOXP3, CD14, and ARG1 in Neuroblastoma Tumor Tissue from High-Risk Patients Predicts Event-Free and Overall Survival. Biomed Res Int 2015:347867.
276Khan FH et.al. (2015). Acquired genetic alterations in tumor cells dictate the development of high-risk neuroblastoma and clinical outcomes. BMC Cancer 15:514.
275Ochodnicka-Mackovicova K et.al. (2015). NF-kappaB and AKT signaling prevent DNA damage in transformed pre-B cells by suppressing RAG1/2 expression and activity. Blood 126:1324-35.
274Khan FH et.al. (2015). Reorganization of metastamiRs in the evolution of metastatic aggressive neuroblastoma cells. BMC Genomics 16:501.
273Eleveld TF et.al. (2015). Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet 47:864-71.
272Sahay D et.al. (2015). The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer. Oncotarget 6:20604-20.
271Eling N et.al. (2015). Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. Oncoscience 2:517-32.
270Yco LP et.al. (2015). Effect of sulfasalazine on human neuroblastoma: analysis of sepiapterin reductase (SPR) as a new therapeutic target. BMC Cancer 15:477.
269Larsson K et.al. (2015). COX/mPGES-1/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset. Proc Natl Acad Sci U S A 112:8070-5.
268Stermann A et.al. (2015). Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice. Cancer Immunol Immunother 64:1215-27.
267Cimmino F et.al. (2015). Inhibition of hypoxia inducible factors combined with all-trans retinoic acid treatment enhances glial transdifferentiation of neuroblastoma cells. Sci Rep 5:11158.
266Tummers B et.al. (2015). The interferon-related developmental regulator 1 is used by human papillomavirus to suppress NFkappaB activation. Nat Commun 6:6537.
265Mussai F et.al. (2015). Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity. Cancer Res 75:3043-53.
264Mandriota SJ et.al. (2015). Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism. Oncotarget 6:18558-76.
263Xiang X et.al. (2015). miRNA-584-5p exerts tumor suppressive functions in human neuroblastoma through repressing transcription of matrix metalloproteinase 14. Biochim Biophys Acta 1852:1743-54.
262Boer JM et.al. (2015). BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures. Haematologica 100:e354-7.
261Tian T et.al. (2015). TAZ promotes temozolomide resistance by upregulating MCL-1 in human glioma cells. Biochem Biophys Res Commun 463:638-43.
260Schwermer M et.al. (2015). Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors. Oncotarget 6:15425-35.
259Bunt J et.al. (2015). PAX6 does not regulate Nfia and Nfib expression during neocortical development. Sci Rep 5:10668.
258Young SA et.al. (2015). Integrin alpha4 Enhances Metastasis and May Be Associated with Poor Prognosis in MYCN-low Neuroblastoma. PLoS One 10:e0120815.
257Challagundla KB et.al. (2015). Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy. J Natl Cancer Inst 107:.
256Liu CY et.al. (2015). Vimentin contributes to epithelial-mesenchymal transition cancer cell mechanics by mediating cytoskeletal organization and focal adhesion maturation. Oncotarget 6:15966-83.
255Pajtler KW et.al. (2015). Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell 27:728-43.
254Cheung BB et.al. (2015). Thymosin-beta4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma. Mol Oncol 9:1484-500.
253Fatrai S et.al. (2015). Maintenance of Clonogenic KIT(+) Human Colon Tumor Cells Requires Secretion of Stem Cell Factor by Differentiated Tumor Cells. Gastroenterology 149:692-704.
252van de Wetering M et.al. (2015). Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161:933-45.
251Kuo YT et.al. (2015). JARID1B Expression Plays a Critical Role in Chemoresistance and Stem Cell-Like Phenotype of Neuroblastoma Cells. PLoS One 10:e0125343.
250Wang M et.al. (2015). Transcriptional co-activator TAZ sustains proliferation and tumorigenicity of neuroblastoma by targeting CTGF and PDGF-beta. Oncotarget 6:9517-30.
249Delic S et.al. (2015). Systematic investigation of CMTM family genes suggests relevance to glioblastoma pathogenesis and CMTM1 and CMTM3 as priority targets. Genes Chromosomes Cancer 54:433-43.
248Cheon DJ et.al. (2015). ADAM12 is a prognostic factor associated with an aggressive molecular subtype of high-grade serous ovarian carcinoma. Carcinogenesis 36:739-47.
247Yang J et.al. (2015). The role of histone demethylase KDM4B in Myc signaling in neuroblastoma. J Natl Cancer Inst 107:djv080.
246Cheng P et.al. (2015). Kinome-wide shRNA screen identifies the receptor tyrosine kinase AXL as a key regulator for mesenchymal glioblastoma stem-like cells. Stem Cell Reports 4:899-913.
245Salm F et.al. (2015). The Phosphoinositide 3-Kinase p110alpha Isoform Regulates Leukemia Inhibitory Factor Receptor Expression via c-Myc and miR-125b to Promote Cell Proliferation in Medulloblastoma. PLoS One 10:e0123958.
244Hamidian A et.al. (2015). Differential regulation of HIF-1alpha and HIF-2alpha in neuroblastoma: Estrogen-related receptor alpha (ERRalpha) regulates HIF2A transcription and correlates to poor outcome. Biochem Biophys Res Commun 461:560-7.
243Vaillant C et.al. (2015). Serpine2/PN-1 Is Required for Proliferative Expansion of Pre-Neoplastic Lesions and Malignant Progression to Medulloblastoma. PLoS One 10:e0124870.
242Li D et.al. (2015). Intelectin 1 suppresses the growth, invasion and metastasis of neuroblastoma cells through up-regulation of N-myc downstream regulated gene 2. Mol Cancer 14:47.
241Bui TT et.al. (2015). gamma-Glutamyl transferase 7 is a novel regulator of glioblastoma growth. BMC Cancer 15:225.
240Chakrabarti G et.al. (2015). Expanding antitumor therapeutic windows by targeting cancer-specific nicotinamide adenine dinucleotide phosphate-biogenesis pathways. Clin Pharmacol 7:57-68.
239Perez-Gomez E et.al. (2015). Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer. Acta Neuropathol Commun 107:djv077.
238Ecker J et.al. (2015). Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma. Acta Neuropathol Commun 3:22.
237Frei K et.al. (2015). Transforming growth factor-beta pathway activity in glioblastoma. Oncotarget 6:5963-77.
236Schmid CA et.al. (2015). DUSP4 deficiency caused by promoter hypermethylation drives JNK signaling and tumor cell survival in diffuse large B cell lymphoma. J Exp Med 212:775-92.
235Evans L et.al. (2015). SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma. Cancer Lett 363:37-45.
234Sanden E et.al. (2015). Aberrant immunostaining pattern of the CD24 glycoprotein in clinical samples and experimental models of pediatric medulloblastomas. J Neurooncol 123:1-13.
233Pahl JH et.al. (2015). Expression of the immune regulation antigen CD70 in osteosarcoma. Cancer Cell Int 15:31.
232Wylie LA et.al. (2015). Ascl1 phospho-status regulates neuronal differentiation in a Xenopus developmental model of neuroblastoma. Dis Model Mech 8:429-41.
231Vellinga TT et.al. (2015). SIRT1/PGC1alpha-Dependent Increase in Oxidative Phosphorylation Supports Chemotherapy Resistance of Colon Cancer. Clin Cancer Res 21:2870-9.
230Yanez Y et.al. (2015). Two independent epigenetic biomarkers predict survival in neuroblastoma. Clin Epigenetics 7:16.
229Zhao Z et.al. (2015). microRNA-449a functions as a tumor suppressor in neuroblastoma through inducing cell differentiation and cell cycle arrest. RNA Biol 12:538-54.
228Yang R et.al. (2015). HDAC9 promotes glioblastoma growth via TAZ-mediated EGFR pathway activation. Oncotarget 6:7644-56.
227Baranski Z et.al. (2015). Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma. J Pathol 236:348-59.
226Bell JL et.al. (2015). IGF2BP1 harbors prognostic significance by gene gain and diverse expression in neuroblastoma. J Clin Oncol 33:1285-93.
225Zhang Y et.al. (2015). miR-182 promotes cell growth and invasion by targeting forkhead box F2 transcription factor in colorectal cancer. Oncol Rep 33:2592-8.
224Mussai F et.al. (2015). Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target. Blood 125:2386-96.
223Song R et.al. (2015). Connecting rules from paired miRNA and mRNA expression data sets of HCV patients to detect both inverse and positive regulatory relationships. BMC Genomics 16 Suppl 2:S11.
222Rettig I et.al. (2015). Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation. Cell Death Dis 6:e1657.
221Wegert J et.al. (2015). Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors. Cancer Cell 27:298-311.
220Richter M et.al. (2015). WIP1 phosphatase as a potential therapeutic target in neuroblastoma. PLoS One 10:e0115635.
219von Stedingk K et.al. (2015). Individual patient risk stratification of high-risk neuroblastomas using a two-gene score suited for clinical use. Int J Cancer 137:868-77.
218Ouyang Q et.al. (2015). Neurotensin promotes the progression of malignant glioma through NTSR1 and impacts the prognosis of glioma patients. Mol Cancer 14:21.
217Chen J et.al. (2015). The genetics of splicing in neuroblastoma. Cancer Discov 5:380-95.
216Santhana Kumar K et.al. (2015). The Ser/Thr kinase MAP4K4 drives c-Met-induced motility and invasiveness in a cell-based model of SHH medulloblastoma. Springerplus 4:19.
215Amoroso F et.al. (2015). The P2X7 receptor is a key modulator of the PI3K/GSK3beta/VEGF signaling network: evidence in experimental neuroblastoma. Oncogene 34:5240-51.
214Qu H et.al. (2015). miRNA-558 promotes tumorigenesis and aggressiveness of neuroblastoma cells through activating the transcription of heparanase. Hum Mol Genet 24:2539-51.
213Xiang X et.al. (2015). Hepatocyte nuclear factor 4 alpha promotes the invasion, metastasis and angiogenesis of neuroblastoma cells via targeting matrix metalloproteinase 14. Cancer Lett 359:187-97.
212Zhao S et.al. (2015). NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma. Oncogene 34:5069-79.
211Wang F et.al. (2015). A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma. Oncotarget 6:2709-24.
210Nasser MW et.al. (2015). RAGE mediates S100A7-induced breast cancer growth and metastasis by modulating the tumor microenvironment. Cancer Res 75:974-85.
209Newman EA et.al. (2015). Alternative NHEJ Pathway Components Are Therapeutic Targets in High-Risk Neuroblastoma. Mol Cancer Res 13:470-82.
208Nakaguro M et.al. (2015). Nucleolar protein PES1 is a marker of neuroblastoma outcome and is associated with neuroblastoma differentiation. Cancer Sci 106:237-43.
207Hartomo TB et.al. (2015). Involvement of aldehyde dehydrogenase 1A2 in the regulation of cancer stem cell properties in neuroblastoma. Int J Oncol 46:1089-98.
206Ren X et.al. (2015). Quantitative nuclear proteomics identifies that miR-137-mediated EZH2 reduction regulates resveratrol-induced apoptosis of neuroblastoma cells. Mol Cell Proteomics 14:316-28.
205Park JH et.al. (2015). Protein arginine methyltransferase 5 is a key regulator of the MYCN oncoprotein in neuroblastoma cells. Mol Oncol 9:617-27.
204Yang HW et.al. (2015). A small subunit processome protein promotes cancer by altering translation. Oncogene 34:4471-81.
203Ryland KE et.al. (2015). Polycomb-dependent repression of the potassium channel-encoding gene KCNA5 promotes cancer cell survival under conditions of stress. Oncogene 34:4591-600.
202Krause S et.al. (2015). Mer tyrosine kinase promotes the survival of t(1;19)-positive acute lymphoblastic leukemia (ALL) in the central nervous system (CNS). Blood 125:820-30.
201Unland R et.al. (2015). Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines. Anticancer Drugs 26:301-11.
200Cwiek P et.al. (2015). RNA interference screening identifies a novel role for PCTK1/CDK16 in medulloblastoma with c-Myc amplification. Oncotarget 6:116-29.
199Bartfeld S et.al. (2015). In vitro expansion of human gastric epithelial stem cells and their responses to bacterial infection. Gastroenterology 148:126-136.e6.
198Beckers A et.al. (2015). MYCN-targeting miRNAs are predominantly downregulated during MYCNdriven neuroblastoma tumor formation. Oncotarget 6:5204-16.
197Harter PN et.al. (2015). Paired box gene 8 (PAX8) expression is associated with sonic hedgehog (SHH)/wingless int (WNT) subtypes, desmoplastic histology and patient survival in human medulloblastomas. Neuropathol Appl Neurobiol 41:165-79.
196Nitta RT et.al. (2015). Casein kinase 2alpha regulates glioblastoma brain tumor-initiating cell growth through the beta-catenin pathway. Oncogene 34:3688-99.
195Zeiner PS et.al. (2015). MIF Receptor CD74 is Restricted to Microglia/Macrophages, Associated with a M1-Polarized Immune Milieu and Prolonged Patient Survival in Gliomas. Brain Pathol 25:491-504.
194Fernandez S et.al. (2015). miR-340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of p27 in non-small cell lung cancer. Oncogene 34:3240-50.
193Harvey H et.al. (2015). Modulation of chemotherapeutic drug resistance in neuroblastoma SK-N-AS cells by the neural apoptosis inhibitory protein and miR-520f. Int J Cancer 136:1579-88.
192Ott M et.al. (2015). Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway. Glia 63:78-90.
191Kobayashi T et.al. (2015). Deubiquitinating activity of CYLD is impaired by SUMOylation in neuroblastoma cells. Oncogene 34:2251-60.
190Shimozato O et.al. (2015). Receptor-type protein tyrosine phosphatase kappa directly dephosphorylates CD133 and regulates downstream AKT activation. Oncogene 34:1949-60.
189Buss MC et.al. (2015). The WIP1 oncogene promotes progression and invasion of aggressive medulloblastoma variants. Oncogene 34:1126-40.
2014 (n=61)
188Pandey GK et.al. (2014). The risk-associated long noncoding RNA NBAT-1 controls neuroblastoma progression by regulating cell proliferation and neuronal differentiation. Cancer Cell 26:722-37.
187Simmini S et.al. (2014). Transformation of intestinal stem cells into gastric stem cells on loss of transcription factor Cdx2. Nat Commun 5:5728.
186Saini RK et.al. (2014). Proteomics of dedifferentiation of SK-N-BE2 neuroblastoma cells. Biochem Biophys Res Commun 454:202-9.
185Pajtler KW et.al. (2014). Neuroblastoma in dialog with its stroma: NTRK1 is a regulator of cellular cross-talk with Schwann cells. Oncotarget 5:11180-92.
184Chavali PL et.al. (2014). TLX activates MMP-2, promotes self-renewal of tumor spheres in neuroblastoma and correlates with poor patient survival. Cell Death Dis 5:e1502.
183Bandino A et.al. (2014). Deoxyhypusine synthase (DHPS) inhibitor GC7 induces p21/Rb-mediated inhibition of tumor cell growth and DHPS expression correlates with poor prognosis in neuroblastoma patients. Cell Oncol (Dordr) 37:387-98.
182Lee S et.al. (2014). Robust selection of cancer survival signatures from high-throughput genomic data using two-fold subsampling. PLoS One 9:e108818.
181Zhang Z et.al. (2014). N-Myc-induced up-regulation of TRPM6/TRPM7 channels promotes neuroblastoma cell proliferation. Oncotarget 5:7625-34.
180van Keimpema M et.al. (2014). FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-kappaB to promote survival of human B cells. Blood 124:3431-40.
179Emmink BL et.al. (2014). GPx2 suppression of H2O2 stress links the formation of differentiated tumor mass to metastatic capacity in colorectal cancer. Cancer Res 74:6717-30.
178Jasinski-Bergner S et.al. (2014). Identification of 14-3-3beta gene as a novel miR-152 target using a proteome-based approach. J Biol Chem 289:31121-35.
177Ke XX et.al. (2014). Inhibition of H3K9 methyltransferase G9a repressed cell proliferation and induced autophagy in neuroblastoma cells. PLoS One 9:e106962.
176Sero V et.al. (2014). Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance. Invest New Drugs 32:1167-80.
175DAsti E et.al. (2014). Coagulation and angiogenic gene expression profiles are defined by molecular subgroups of medulloblastoma: evidence for growth factor-thrombin cross-talk. J Thromb Haemost 12:1838-49.
174Izumi H et.al. (2014). Trim32 facilitates degradation of MYCN on spindle poles and induces asymmetric cell division in human neuroblastoma cells. Cancer Res 74:5620-30.
173Basak O et.al. (2014). Mapping early fate determination in Lgr5+ crypt stem cells using a novel Ki67-RFP allele. EMBO J 33:2057-68.
172Cangelosi D et.al. (2014). Use of Attribute Driven Incremental Discretization and Logic Learning Machine to build a prognostic classifier for neuroblastoma patients. BMC Bioinformatics 15 Suppl 5:S4.
171Rack PG et.al. (2014). Arhgap36-dependent activation of Gli transcription factors. Proc Natl Acad Sci U S A 111:11061-6.
170Rutten MJ et.al. (2014). HLA-G expression is an independent predictor for improved survival in high grade ovarian carcinomas. J Immunol Res 2014:274584.
169Weichhaus M et.al. (2014). Osteoprotegerin expression in triple-negative breast cancer cells promotes metastasis. Cancer Med 3:1112-25.
168Forget A et.al. (2014). Shh signaling protects Atoh1 from degradation mediated by the E3 ubiquitin ligase Huwe1 in neural precursors. Dev Cell 29:649-61.
167Shahbazi J et.al. (2014). Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1. Oncotarget 5:4257-68.
166Tummers B et.al. (2014). CD40-mediated amplification of local immunity by epithelial cells is impaired by HPV. J Invest Dermatol 134:2918-2927.
165Hiddingh L et.al. (2014). Identification of temozolomide resistance factors in glioblastoma via integrative miRNA/mRNA regulatory network analysis. Sci Rep 4:5260.
164De Antonellis P et.al. (2014). Early targets of miR-34a in neuroblastoma. Mol Cell Proteomics 13:2114-31.
163Liu PY et.al. (2014). Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression. J Natl Cancer Inst 106:.
162Jeibmann A et.al. (2014). Identification of genes involved in the biology of atypical teratoid/rhabdoid tumours using Drosophila melanogaster. Nat Commun 5:4005.
161Quandt D et.al. (2014). Synergistic effects of IL-4 and TNFalpha on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation. J Transl Med 12:151.
160Wille C et.al. (2014). Protein Kinase D family kinases: roads start to segregate. Bioarchitecture 4:111-5.
159Hovestadt V et.al. (2014). Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. Nature 510:537-41.
158Zhu Z et.al. (2014). Targeting self-renewal in high-grade brain tumors leads to loss of brain tumor stem cells and prolonged survival. Cell Stem Cell 15:185-98.
157Tomiyama A et.al. (2014). Flotillin-1 regulates oncogenic signaling in neuroblastoma cells by regulating ALK membrane association. Cancer Res 74:3790-801.
156David M et.al. (2014). Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers. PLoS One 9:e97771.
155Venkataraman S et.al. (2014). Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget 5:2355-71.
154Fiaschetti G et.al. (2014). NOTCH ligands JAG1 and JAG2 as critical pro-survival factors in childhood medulloblastoma. Acta Neuropathol Commun 2:39.
153Litzenburger UM et.al. (2014). Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget 5:1038-51.
152Kool M et.al. (2014). Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell 25:393-405.
151Kerami Z et.al. (2014). Effect of interleukin-17 on gene expression profile of fibroblasts from Crohns disease patients. J Crohns Colitis 8:1208-16.
150van Buul JD et.al. (2014). Rho GAPs and GEFs: controling switches in endothelial cell adhesion. Cell Adh Migr 8:108-24.
149Koso H et.al. (2014). Identification of FoxR2 as an oncogene in medulloblastoma. Cancer Res 74:2351-61.
148Yamaguchi Y et.al. (2014). Novel 1p tumour suppressor Dnmt1-associated protein 1 regulates MYCN/ataxia telangiectasia mutated/p53 pathway. Eur J Cancer 50:1555-65.
147Laetsch TW et.al. (2014). Multiple components of the spliceosome regulate Mcl1 activity in neuroblastoma. Cell Death Dis 5:e1072.
146Murakami-Tonami Y et.al. (2014). Inactivation of SMC2 shows a synergistic lethal response in MYCN-amplified neuroblastoma cells. Cell Cycle 13:1115-31.
145Xu B et.al. (2014). Regulation of endometrial receptivity by the highly expressed HOXA9, HOXA11 and HOXD10 HOX-class homeobox genes. Hum Reprod 29:781-90.
144Bageritz J et.al. (2014). Stem cell characteristics in glioblastoma are maintained by the ecto-nucleotidase E-NPP1. Cell Death Differ 21:929-40.
143Hiddingh L et.al. (2014). EFEMP1 induces gamma-secretase/Notch-mediated temozolomide resistance in glioblastoma. Oncotarget 5:363-74.
142van Vuurden DG et.al. (2014). Pre-B-cell leukemia homeobox interacting protein 1 is overexpressed in astrocytoma and promotes tumor cell growth and migration. Neuro Oncol 16:946-59.
141Chen ZX et.al. (2014). RNA helicase A is a downstream mediator of KIF1Bbeta tumor-suppressor function in neuroblastoma. Cancer Discov 4:434-51.
140Kerl K et.al. (2014). Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1. Int J Cancer 135:989-95.
139Fabian J et.al. (2014). GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3. Cancer Res 74:2604-16.
138Wolter JK et.al. (2014). Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma. Oncotarget 5:161-72.
137Wirsching HG et.al. (2014). Thymosin beta 4 gene silencing decreases stemness and invasiveness in glioblastoma. Brain 137:433-48.
136Fiaschetti G et.al. (2014). Epigenetic silencing of miRNA-9 is associated with HES1 oncogenic activity and poor prognosis of medulloblastoma. Br J Cancer 110:636-47.
135Fryer LG et.al. (2014). The endoplasmic reticulum coat protein II transport machinery coordinates cellular lipid secretion and cholesterol biosynthesis. J Biol Chem 289:4244-61.
134Wille C et.al. (2014). Protein kinase D2 induces invasion of pancreatic cancer cells by regulating matrix metalloproteinases. Mol Biol Cell 25:324-36.
133Barbieri E et.al. (2014). Histone chaperone CHAF1A inhibits differentiation and promotes aggressive neuroblastoma. Cancer Res 74:765-74.
132Bate-Eya LT et.al. (2014). Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumours. Eur J Cancer 50:628-37.
131Erdreich-Epstein A et.al. (2014). PID1 (NYGGF4), a new growth-inhibitory gene in embryonal brain tumors and gliomas. Clin Cancer Res 20:827-36.
130Sengupta S et.al. (2014). alpha5-GABAA receptors negatively regulate MYC-amplified medulloblastoma growth. Acta Neuropathol 127:593-603.
129Lange I et.al. (2014). Novel interaction of ornithine decarboxylase with sepiapterin reductase regulates neuroblastoma cell proliferation. J Mol Biol 426:332-46.
128Milla LA et.al. (2014). Neogenin1 is a Sonic Hedgehog target in medulloblastoma and is necessary for cell cycle progression. Int J Cancer 134:21-31.
2013 (n=55)
127Ecker J et.al. (2013). Targeting of histone deacetylases in brain tumors. CNS Oncol 2:359-76.
126Barbieri E et.al. (2013). A p53 drug response signature identifies prognostic genes in high-risk neuroblastoma. PLoS One 8:e79843.
125Ding J et.al. (2013). The histone H3 methyltransferase G9A epigenetically activates the serine-glycine synthesis pathway to sustain cancer cell survival and proliferation. Cell Metab 18:896-907.
124Li D et.al. (2013). FOXD3 is a novel tumor suppressor that affects growth, invasion, metastasis and angiogenesis of neuroblastoma. Oncotarget 4:2021-44.
123Pajtler KW et.al. (2013). The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma. Acta Neuropathol Commun 1:19.
122Whittier KL et.al. (2013). G-protein coupled receptor expression patterns delineate medulloblastoma subgroups. Acta Neuropathol Commun 1:66.
121Bergiers I et.al. (2013). The homeodomain transcription factor Hoxa2 interacts with and promotes the proteasomal degradation of the E3 ubiquitin protein ligase RCHY1. PLoS One 8:e80387.
120Henssen A et.al. (2013). BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. Oncotarget 4:2080-95.
119Ingram WJ et.al. (2013). ABC transporter activity linked to radiation resistance and molecular subtype in pediatric medulloblastoma. Exp Hematol Oncol 2:26.
118Totaro F et.al. (2013). Impact of interleukin-6 -174 G>C gene promoter polymorphism on neuroblastoma. PLoS One 8:e76810.
117Remke M et.al. (2013). TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol 126:917-29.
116Jager N et.al. (2013). Hypermutation of the inactive X chromosome is a frequent event in cancer. Cell 155:567-81.
115Fan YH et.al. (2013). USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis. Cell Death Dis 4:e867.
114Tavanti E et.al. (2013). Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma. Br J Cancer 109:2607-18.
113Stange DE et.al. (2013). Differentiated Troy+ chief cells act as reserve stem cells to generate all lineages of the stomach epithelium. Cell 155:357-68.
112Djos A et.al. (2013). Aneuploidy in neuroblastoma tumors is not associated with inactivating point mutations in the STAG2 gene. BMC Med Genet 14:102.
111Pascutti MF et.al. (2013). IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. Blood 122:3010-9.
110Tan F et.al. (2013). Dihydropyrimidinase-like protein 3 expression is negatively regulated by MYCN and associated with clinical outcome in neuroblastoma. Cancer Sci 104:1586-92.
109Zeilstra J et.al. (2013). CD44 expression in intestinal epithelium and colorectal cancer is independent of p53 status. PLoS One 8:e72849.
108Snoeren N et.al. (2013). Maspin is a marker for early recurrence in primary stage III and IV colorectal cancer. Br J Cancer 109:1636-47.
107Tannous BA et.al. (2013). Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs. J Natl Cancer Inst 105:1322-31.
106Spina R et.al. (2013). Critical role of zinc finger protein 521 in the control of growth, clonogenicity and tumorigenic potential of medulloblastoma cells. Oncotarget 4:1280-92.
105Shi K et.al. (2013). Protease-activated receptor-2 induces migration of pancreatic cancer cells in an extracellular ATP-dependent manner. J Thromb Haemost 11:1892-902.
104Wilzen A et.al. (2013). ERBB3 is a marker of a ganglioneuroblastoma/ganglioneuroma-like expression profile in neuroblastic tumours. Mol Cancer 12:70.
103Feng W et.al. (2013). The chromatin remodeler CHD7 regulates adult neurogenesis via activation of SoxC transcription factors. Cell Stem Cell 13:62-72.
102Jones DT et.al. (2013). Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 45:927-32.
101Cangelosi D et.al. (2013). Logic Learning Machine creates explicit and stable rules stratifying neuroblastoma patients. BMC Bioinformatics 14 Suppl 7:S12.
100Oehme I et.al. (2013). Histone deacetylase 10 promotes autophagy-mediated cell survival. Proc Natl Acad Sci U S A 110:E2592-601.
99Abba M et.al. (2013). Unraveling the role of FOXQ1 in colorectal cancer metastasis. Mol Cancer Res 11:1017-28.
98Kaaij LT et.al. (2013). DNA methylation dynamics during intestinal stem cell differentiation reveals enhancers driving gene expression in the villus. Genome Biol 14:R50.
97Leprivier G et.al. (2013). The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell 153:1064-79.
96Tomaselli S et.al. (2013). ADAR2 editing activity in newly diagnosed versus relapsed pediatric high-grade astrocytomas. BMC Cancer 13:255.
95Remke M et.al. (2013). Somatostatin receptor subtype 2 (sst(2)) is a potential prognostic marker and a therapeutic target in medulloblastoma. Childs Nerv Syst 29:1253-62.
94Gramatzki D et.al. (2013). Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway. PLoS One 8:e63527.
93van Nes J et.al. (2013). A NOTCH3 transcriptional module induces cell motility in neuroblastoma. Clin Cancer Res 19:3485-94.
92Veringa SJ et.al. (2013). In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma. PLoS One 8:e61512.
91Fransson S et.al. (2013). Aggressive neuroblastomas have high p110alpha but low p110delta and p55alpha/p50alpha protein levels compared to low stage neuroblastomas. J Mol Signal 8:4.
90Valdora F et.al. (2013). Epigenetic Silencing of DKK3 in medulloblastoma. Int J Mol Sci 14:7492-505.
89Lundberg G et.al. (2013). Intratumour diversity of chromosome copy numbers in neuroblastoma mediated by on-going chromosome loss from a polyploid state. PLoS One 8:e59268.
88Sahm F et.al. (2013). The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress. Cancer Res 73:3225-34.
87Creevey L et.al. (2013). MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1. Mol Cancer 12:23.
86Mohlin S et.al. (2013). HIF2A and IGF2 expression correlates in human neuroblastoma cells and normal immature sympathetic neuroblasts. Neoplasia 15:328-34.
85Carotenuto M et.al. (2013). Neuroblastoma tumorigenesis is regulated through the Nm23-H1/h-Prune C-terminal interaction. Sci Rep 3:1351.
84Pettersen I et.al. (2013). Expression of TWEAK/Fn14 in neuroblastoma: implications in tumorigenesis. Int J Oncol 42:1239-48.
83Steller EJ et.al. (2013). PDGFRB promotes liver metastasis formation of mesenchymal-like colorectal tumor cells. Neoplasia 15:204-17.
82Yco LP et.al. (2013). PRAF2 stimulates cell proliferation and migration and predicts poor prognosis in neuroblastoma. Int J Oncol 42:1408-16.
81Koomoa DL et.al. (2013). DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma. Int J Oncol 42:1219-28.
80Pajtler KW et.al. (2013). Expression of NTRK1/TrkA affects immunogenicity of neuroblastoma cells. Int J Cancer 133:908-19.
79Santo EE et.al. (2013). FOXO3a is a major target of inactivation by PI3K/AKT signaling in aggressive neuroblastoma. Cancer Res 73:2189-98.
78Caretti V et.al. (2013). WEE1 kinase inhibition enhances the radiation response of diffuse intrinsic pontine gliomas. Mol Cancer Ther 12:141-50.
77Zhu Y et.al. (2013). Modulation of serines 17 and 24 in the LC3-interacting region of Bnip3 determines pro-survival mitophagy versus apoptosis. J Biol Chem 288:1099-113.
76Wickstrom M et.al. (2013). Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo. Int J Cancer 132:1516-24.
75Sung PJ et.al. (2013). Identification and characterisation of STMN4 and ROBO2 gene involvement in neuroblastoma cell differentiation. Cancer Lett 328:168-75.
74Nakata S et.al. (2013). LGR5 is a marker of poor prognosis in glioblastoma and is required for survival of brain cancer stem-like cells. Brain Pathol 23:60-72.
73Das S et.al. (2013). Modulation of neuroblastoma disease pathogenesis by an extensive network of epigenetically regulated microRNAs. Oncogene 32:2927-36.
2012 (n=36)
72Salih DA et.al. (2012). FoxO6 regulates memory consolidation and synaptic function. Genes Dev 26:2780-801.
71Korshunov A et.al. (2012). LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). Acta Neuropathol 124:875-81.
70Valentijn LJ et.al. (2012). Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc Natl Acad Sci U S A 109:19190-5.
69Sturm D et.al. (2012). Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425-37.
68Schramm A et.al. (2012). Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome. Br J Cancer 107:1409-17.
67Molenaar JJ et.al. (2012). LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet 44:1199-206.
66von Bueren AO et.al. (2012). Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours. Br J Cancer 107:1399-408.
65Diskin SJ et.al. (2012). Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma. Nat Genet 44:1126-30.
64Liu XY et.al. (2012). Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 124:615-25.
63Jones DT et.al. (2012). Dissecting the genomic complexity underlying medulloblastoma. Nature 488:100-5.
62Lamers F et.al. (2012). Identification of BIRC6 as a novel intervention target for neuroblastoma therapy. BMC Cancer 12:285.
61Wernicke CM et.al. (2012). MondoA is highly overexpressed in acute lymphoblastic leukemia cells and modulates their metabolism, differentiation and survival. Leuk Res 36:1185-92.
60Smits M et.al. (2012). EZH2-regulated DAB2IP is a medulloblastoma tumor suppressor and a positive marker for survival. Clin Cancer Res 18:4048-58.
59Geurts van Kessel A et.al. (2012). New insights and clinical advancements in cellular oncology. Cell Oncol (Dordr) 35:139-47.
58Munoz J et.al. (2012). The Lgr5 intestinal stem cell signature: robust expression of proposed quiescent +4 cell markers. EMBO J 31:3079-91.
57Kunkele A et.al. (2012). Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas. Neuro Oncol 14:859-69.
56Lawlor ER et.al. (2012). Epigenetic changes in pediatric solid tumors: promising new targets. Clin Cancer Res 18:2768-79.
55Milde T et.al. (2012). Nestin expression identifies ependymoma patients with poor outcome. Brain Pathol 22:848-60.
54Cornero A et.al. (2012). Design of a multi-signature ensemble classifier predicting neuroblastoma patients outcome. BMC Bioinformatics 13 Suppl 4:S13.
53Kemper K et.al. (2012). Mutations in the Ras-Raf Axis underlie the prognostic value of CD133 in colorectal cancer. Clin Cancer Res 18:3132-41.
52Lynch J et.al. (2012). MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-beta signalling pathway. Carcinogenesis 33:976-85.
51Molenaar JJ et.al. (2012). Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 483:589-93.
50Lamers F et.al. (2012). Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth. Eur J Cancer 48:3093-103.
49Kool M et.al. (2012). Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 123:473-84.
48Grammel D et.al. (2012). Sonic hedgehog-associated medulloblastoma arising from the cochlear nuclei of the brainstem. Acta Neuropathol 123:601-14.
47Meehan M et.al. (2012). Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase A oncogene. Mol Cancer 11:6.
46Rasmuson A et.al. (2012). Autocrine prostaglandin E2 signaling promotes tumor cell survival and proliferation in childhood neuroblastoma. PLoS One 7:e29331.
45Gawecka JE et.al. (2012). PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma. Int J Cancer 131:1556-68.
44Dittmann LM et.al. (2012). Downregulation of PRDX1 by promoter hypermethylation is frequent in 1p/19q-deleted oligodendroglial tumours and increases radio Oncogene 31:3409-18.
43Hoogewijs D et.al. (2012). Androglobin: a chimeric globin in metazoans that is preferentially expressed in Mammalian testes. Mol Biol Evol 29:1105-14.
42Sulzmaier FJ et.al. (2012). PEA-15 potentiates H-Ras-mediated epithelial cell transformation through phospholipase D. Oncogene 31:3547-60.
41Lamers F et.al. (2012). Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression. Eur J Cancer 48:763-71.
40Wang C et.al. (2012). EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR. Cancer Res 72:315-24.
39Molenaar JJ et.al. (2012). Copy number defects of G1-cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis. Genes Chromosomes Cancer 51:10-9.
38Bunt J et.al. (2012). OTX2 directly activates cell cycle genes and inhibits differentiation in medulloblastoma cells. Int J Cancer 131:E21-32.
37Santo EE et.al. (2012). Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma. Oncogene 31:1571-81.
2011 (n=10)
36Thomas DM et.al. (2011). Workshop Report on the European Bone Sarcoma Networking Meeting: Integration of Clinical Trials with Tumor Biology. J Adolesc Young Adult Oncol 1:118-23.
35van Vuurden DG et.al. (2011). PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget 2:984-96.
34de Sousa E Melo F et.al. (2011). Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. Cell Stem Cell 9:476-85.
33Bunt J et.al. (2011). Joint binding of OTX2 and MYC in promotor regions is associated with high gene expression in medulloblastoma. PLoS One 6:e26058.
32Lamers F et.al. (2011). Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe. Endocr Relat Cancer 18:657-68.
31Haug BH et.al. (2011). MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma. Carcinogenesis 32:1005-12.
30Murphy DM et.al. (2011). Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis. Mol Carcinog 50:403-11.
29PosthumaDeBoer J et.al. (2011). WEE1 inhibition sensitizes osteosarcoma to radiotherapy. BMC Cancer 11:156.
28Liu Z et.al. (2011). CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression. Cell Death Differ 18:1174-83.
27Buckley PG et.al. (2011). Genome-wide DNA methylation analysis of neuroblastic tumors reveals clinically relevant epigenetic events and large-scale epigenomic alterations localized to telomeric regions. Int J Cancer 128:2296-305.
2010 (n=8)
26Bunt J et.al. (2010). Regulation of cell cycle genes and induction of senescence by overexpression of OTX2 in medulloblastoma cell lines. Mol Cancer Res 8:1344-57.
25Mergui X et.al. (2010). p21Waf1 expression is regulated by nuclear intermediate filament vimentin in neuroblastoma. BMC Cancer 10:473.
24Holzel M et.al. (2010). NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 142:218-29.
23Borsics T et.al. (2010). Subcellular distribution and expression of prenylated Rab acceptor 1 domain family, member 2 (PRAF2) in malignant glioma: Influence on cell survival and migration. Cancer Sci 101:1624-31.
22Verissimo CS et.al. (2010). Silencing of the microtubule-associated proteins doublecortin-like and doublecortin-like kinase-long induces apoptosis in neuroblastoma cells. Endocr Relat Cancer 17:399-414.
21Molenaar JJ et.al. (2010). Cyclin D1 is a direct transcriptional target of GATA3 in neuroblastoma tumor cells. Oncogene 29:2739-45.
20Geerts D et.al. (2010). The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification. Int J Cancer 126:2012-24.
19Revet I et.al. (2010). MSX1 induces the Wnt pathway antagonist genes DKK1, DKK2, DKK3, and SFRP1 in neuroblastoma cells, but does not block Wnt3 and Wnt5A signalling to DVL3. Cancer Lett 289:195-207.
2009 (n=7)
18Molenaar JJ et.al. (2009). Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proc Natl Acad Sci U S A 106:12968-73.
17Cimmino F et.al. (2009). Galectin-1 is a major effector of TrkB-mediated neuroblastoma aggressiveness. Oncogene 28:2015-23.
16Huang S et.al. (2009). ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Cancer Cell 15:328-40.
15van Hooff SR et.al. (2009). The construction of genome-based transcriptional units. OMICS 13:105-14.
14Missiaglia E et.al. (2009). Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development. Genes Chromosomes Cancer 48:455-67.
13Schulte JH et.al. (2009). Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res 69:2065-71.
12Schulte JH et.al. (2009). The low-affinity neurotrophin receptor, p75, is upregulated in ganglioneuroblastoma/ganglioneuroma and reduces tumorigenicity of neuroblastoma cells in vivo. Int J Cancer 124:2488-94.
2008 (n=5)
11Kool M et.al. (2008). Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 3:e3088.
10Molenaar JJ et.al. (2008). Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. Cancer Res 68:2599-609.
9Revet I et.al. (2008). The MSX1 homeobox transcription factor is a downstream target of PHOX2B and activates the Delta-Notch pathway in neuroblastoma. Exp Cell Res 314:707-19.
8Merks JH et.al. (2008). Prevalence and patterns of morphological abnormalities in patients with childhood cancer. JAMA 299:61-9.
7Koppen A et.al. (2008). Dickkopf-3 expression is a marker for neuroblastic tumor maturation and is down-regulated by MYCN. Int J Cancer 122:1455-64.
2007 (n=4)
6Geerts D et.al. (2007). Expression of prenylated Rab acceptor 1 domain family, member 2 (PRAF2) in neuroblastoma: correlation with clinical features, cellular localization, and cerulenin-mediated apoptosis regulation. Clin Cancer Res 13:6312-9.
5Koppen A et.al. (2007). Direct regulation of the minichromosome maintenance complex by MYCN in neuroblastoma. Eur J Cancer 43:2413-22.
4Koppen A et.al. (2007). Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation. Cancer Lett 256:218-28.
3Mainguy G et.al. (2007). Extensive polycistronism and antisense transcription in the mammalian Hox clusters. PLoS One 2:e356.
2006 (n=2)
2Sohn SH et.al. (2006). Biological responses in osteoblast-like cell line according to thin layer hydroxyapatite coatings on anodized titanium. J Oral Rehabil 33:898-911.
1Valentijn LJ et.al. (2006). Read-through transcript from NM23-H1 into the neighboring NM23-H2 gene encodes a novel protein, NM23-LV. Genomics 87:483-9.
AMC: OncogenomicsGo to MainOpen_access